{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:48:26Z","timestamp":1794491306440,"version":"4.9.1"},"reference-count":534,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"research project of 988th Hospital of Joint Logistic Support Force of PLA","award":["YNZX2024005"],"award-info":[{"award-number":["YNZX2024005"]}]},{"name":"the joint construction project of Henan Province","award":["LHGJ20230703"],"award-info":[{"award-number":["LHGJ20230703"]}]},{"name":"the opening project of State Key Laboratory of Explosion Science and Technology","award":["KFJJ23-09M"],"award-info":[{"award-number":["KFJJ23-09M"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02046-4","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:04:34Z","timestamp":1749074674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights"],"prefix":"10.1186","volume":"13","author":[{"given":"Hengzeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"12 Suppl 2","key":"2046_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT et al (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2013\u20132017. Neuro Oncol 22(12 Suppl 2):iv1\u2013iv96","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M et al (2024) Glioma. Nat Rev Dis Primers 10(1):33","journal-title":"Nat Rev Dis Primers"},{"key":"2046_CR3","doi-asserted-by":"crossref","unstructured":"Chang C et al (2024) Recurrent Glioblastoma-Molecular underpinnings and evolving treatment paradigms. Int J Mol Sci, 25(12)","DOI":"10.3390\/ijms25126733"},{"issue":"1","key":"2046_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong L, Li N, Zhang Z (2022) Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 41(1):142","journal-title":"J Exp Clin Cancer Res"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"1177440","DOI":"10.3389\/fcell.2023.1177440","volume":"11","author":"A Tonkin-Reeves","year":"2023","unstructured":"Tonkin-Reeves A, Giuliani CM, Price JT (2023) Inhibition of autophagy; an opportunity for the treatment of cancer resistance. Front Cell Dev Biol 11:1177440","journal-title":"Front Cell Dev Biol"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fonc.2019.00485","volume":"9","author":"Z Yang","year":"2019","unstructured":"Yang Z et al (2019) C8-Substituted Imidazotetrazine analogs overcome Temozolomide resistance by inducing DNA adducts and DNA damage. Front Oncol 9:485","journal-title":"Front Oncol"},{"key":"2046_CR7","doi-asserted-by":"crossref","unstructured":"Jeon J et al (2021) Revisiting Platinum-Based anticancer drugs to overcome gliomas. Int J Mol Sci, 22(10):5111","DOI":"10.3390\/ijms22105111"},{"issue":"1","key":"2046_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-020-03529-1","volume":"150","author":"P de Blank","year":"2020","unstructured":"de Blank P, Fouladi M, Huse JT (2020) Molecular markers and targeted therapy in pediatric low-grade glioma. J Neurooncol 150(1):5\u201315","journal-title":"J Neurooncol"},{"issue":"12","key":"2046_CR9","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1002\/hbm.26393","volume":"44","author":"B Shams","year":"2023","unstructured":"Shams B et al (2023) Improved prediction of glioma-related aphasia by diffusion MRI metrics, machine learning, and automated fiber bundle segmentation. Hum Brain Mapp 44(12):4480\u20134497","journal-title":"Hum Brain Mapp"},{"issue":"9","key":"2046_CR10","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.7150\/thno.82005","volume":"13","author":"N Iturrioz-Rodr\u00edguez","year":"2023","unstructured":"Iturrioz-Rodr\u00edguez N, Sampron N, Matheu A (2023) Current advances in Temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics 13(9):2734\u20132756","journal-title":"Theranostics"},{"issue":"7","key":"2046_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK (2023) Glioblastoma and other primary brain malignancies in adults: A review. JAMA 329(7):574\u2013587","journal-title":"JAMA"},{"issue":"1","key":"2046_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-020-1137-5","volume":"19","author":"C Lu","year":"2020","unstructured":"Lu C et al (2020) DNA-methylation-mediated activating of LncRNA SNHG12 promotes Temozolomide resistance in glioblastoma. Mol Cancer 19(1):28","journal-title":"Mol Cancer"},{"key":"2046_CR13","doi-asserted-by":"crossref","unstructured":"Hu J et al (2021) Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme. Sci Adv, 7(5):eabc2511","DOI":"10.1126\/sciadv.abc2511"},{"key":"2046_CR14","doi-asserted-by":"publisher","first-page":"1336476","DOI":"10.3389\/fimmu.2024.1336476","volume":"15","author":"J Collado","year":"2024","unstructured":"Collado J et al (2024) Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy. Front Immunol 15:1336476","journal-title":"Front Immunol"},{"issue":"6","key":"2046_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noac263","volume":"25","author":"V Moreno","year":"2023","unstructured":"Moreno V et al (2023) Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, window-of-opportunity study. Neuro Oncol 25(6):1113\u20131122","journal-title":"Neuro Oncol"},{"issue":"2","key":"2046_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3171\/2019.10.JNS192206","volume":"134","author":"SH Park","year":"2020","unstructured":"Park SH et al (2020) Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J Neurosurg 134(2):475\u2013483","journal-title":"J Neurosurg"},{"issue":"3","key":"2046_CR17","first-page":"287","volume":"3","author":"L Oliver","year":"2020","unstructured":"Oliver L et al (2020) Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist 3(3):287\u2013301","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"2046_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41551-019-0370-y","volume":"3","author":"PA Janmey","year":"2019","unstructured":"Janmey PA, Pogoda K (2019) Compressive tumours cause neuronal damage. Nat Biomed Eng 3(3):171\u2013172","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"2046_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","volume":"22","author":"MC Takenaka","year":"2019","unstructured":"Takenaka MC et al (2019) Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci 22(5):729\u2013740","journal-title":"Nat Neurosci"},{"issue":"29","key":"2046_CR20","doi-asserted-by":"publisher","first-page":"eaba2113","DOI":"10.1126\/sciadv.aba2113","volume":"6","author":"F Jiao","year":"2020","unstructured":"Jiao F et al (2020) RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma. Sci Adv 6(29):eaba2113","journal-title":"Sci Adv"},{"issue":"6605","key":"2046_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.abn7570","volume":"377","author":"K Lin","year":"2022","unstructured":"Lin K et al (2022) Mechanism-based design of agents that selectively target drug-resistant glioma. Science 377(6605):502\u2013511","journal-title":"Science"},{"issue":"12","key":"2046_CR22","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.labinv.2024.102160","volume":"104","author":"K Bomsztyk","year":"2024","unstructured":"Bomsztyk K et al (2024) Analysis of DNA methylation in gliomas: assessment of preanalytical variables. Lab Invest 104(12):102160","journal-title":"Lab Invest"},{"issue":"2","key":"2046_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","volume":"21","author":"A Mansouri","year":"2019","unstructured":"Mansouri A et al (2019) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 21(2):167\u2013178","journal-title":"Neuro Oncol"},{"key":"2046_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2021.01.014","volume":"147","author":"D Gramatzki","year":"2021","unstructured":"Gramatzki D et al (2021) Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to Temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? Eur J Cancer 147:84\u201394","journal-title":"Eur J Cancer"},{"key":"2046_CR25","doi-asserted-by":"crossref","unstructured":"Arcella A et al (2020) Dissecting molecular features of gliomas: genetic loci and validated biomarkers. Int J Mol Sci, 21(2):685","DOI":"10.3390\/ijms21020685"},{"key":"2046_CR26","doi-asserted-by":"crossref","unstructured":"Cruz JVR et al (2022) Obstacles to glioblastoma treatment two decades after Temozolomide. Cancers (Basel), 14(13):3203","DOI":"10.3390\/cancers14133203"},{"key":"2046_CR27","doi-asserted-by":"crossref","unstructured":"Papacocea SI et al (2024) Molecular profile as an outcome predictor in glioblastoma along with MRI features and surgical resection: A scoping review. Int J Mol Sci, 25(17):9714","DOI":"10.3390\/ijms25179714"},{"key":"2046_CR28","doi-asserted-by":"crossref","unstructured":"Brawanski KR et al (2023) Influence of MMR, MGMT promotor methylation and protein expression on overall and Progression-Free survival in primary glioblastoma patients treated with Temozolomide. Int J Mol Sci, 24(7):6184","DOI":"10.3390\/ijms24076184"},{"issue":"8","key":"2046_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/noaa033","volume":"22","author":"A Wick","year":"2020","unstructured":"Wick A et al (2020) Superiority of Temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant Astrocytoma. Neuro Oncol 22(8):1162\u20131172","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13046-020-01641-8","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J et al (2020) Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. J Exp Clin Cancer Res 39(1):137","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2046_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/neuonc\/noac014","volume":"24","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu CMS et al (2022) MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to Temozolomide in IDH-mutant anaplastic Astrocytomas. Neuro Oncol 24(4):665\u2013667","journal-title":"Neuro Oncol"},{"issue":"5","key":"2046_CR32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M et al (2020) MGMT status as a clinical biomarker in glioblastoma. Trends Cancer 6(5):380\u2013391","journal-title":"Trends Cancer"},{"issue":"10","key":"2046_CR33","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","volume":"26","author":"ME Hegi","year":"2024","unstructured":"Hegi ME et al (2024) No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro Oncol 26(10):1867\u20131875","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR34","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1038\/s41467-023-39845-z","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y et al (2023) Lysine methylation promotes NFAT5 activation and determines Temozolomide efficacy in glioblastoma. Nat Commun 14(1):4062","journal-title":"Nat Commun"},{"issue":"3","key":"2046_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/neuonc\/noaa198","volume":"23","author":"E Nie","year":"2021","unstructured":"Nie E et al (2021) TGF-\u03b21 modulates Temozolomide resistance in glioblastoma via altered MicroRNA processing and elevated MGMT. Neuro Oncol 23(3):435\u2013446","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR36","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","volume":"11","author":"B Oldrini","year":"2020","unstructured":"Oldrini B et al (2020) MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun 11(1):3883","journal-title":"Nat Commun"},{"key":"2046_CR37","doi-asserted-by":"crossref","unstructured":"Cheng X et al (2024) Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma. Nat Commun, 15(1):1957","DOI":"10.1038\/s41467-024-45979-5"},{"issue":"35","key":"2046_CR38","doi-asserted-by":"publisher","first-page":"e2308417","DOI":"10.1002\/advs.202308417","volume":"11","author":"J Xu","year":"2024","unstructured":"Xu J et al (2024) MEN1 Deficiency-Driven activation of the \u03b2-Catenin-MGMT Axis promotes pancreatic neuroendocrine tumor growth and confers Temozolomide resistance. Adv Sci (Weinh) 11(35):e2308417","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"2046_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/neuonc\/noab003","volume":"23","author":"S Wu","year":"2021","unstructured":"Wu S et al (2021) PARP-mediated parylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol 23(6):920\u2013931","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","volume":"39","author":"C Lu","year":"2021","unstructured":"Lu C et al (2021) DNA sensing in mismatch Repair-Deficient tumor cells is essential for Anti-tumor immunity. Cancer Cell 39(1):96\u2013108.e6","journal-title":"Cancer Cell"},{"issue":"1","key":"2046_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK (2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther 6(1):254","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2046_CR42","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.7150\/ijbs.71714","volume":"18","author":"Y He","year":"2022","unstructured":"He Y et al (2022) The role of DNA mismatch repair in immunotherapy of human cancer. Int J Biol Sci 18(7):2821\u20132832","journal-title":"Int J Biol Sci"},{"issue":"21","key":"2046_CR43","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.18632\/oncotarget.28090","volume":"12","author":"LH El Touny","year":"2021","unstructured":"El Touny LH et al (2021) ATR Inhibition reverses the resistance of homologous recombination deficient MGMT(low)\/MMR(proficient) cancer cells to Temozolomide. Oncotarget 12(21):2114\u20132130","journal-title":"Oncotarget"},{"issue":"1","key":"2046_CR44","first-page":"vdad165","volume":"6","author":"VWS Leong","year":"2024","unstructured":"Leong VWS et al (2024) MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy. Neurooncol Adv 6(1):vdad165","journal-title":"Neurooncol Adv"},{"issue":"19","key":"2046_CR45","doi-asserted-by":"publisher","first-page":"e2309290","DOI":"10.1002\/advs.202309290","volume":"11","author":"Q Yue","year":"2024","unstructured":"Yue Q et al (2024) Histone H3K9 lactylation confers Temozolomide resistance in glioblastoma via LUC7L2-Mediated MLH1 intron retention. Adv Sci (Weinh) 11(19):e2309290","journal-title":"Adv Sci (Weinh)"},{"issue":"22","key":"2046_CR46","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1158\/0008-5472.CAN-22-2036","volume":"82","author":"T Gan","year":"2022","unstructured":"Gan T et al (2022) MEX3A impairs DNA mismatch repair signaling and mediates acquired Temozolomide resistance in glioblastoma. Cancer Res 82(22):4234\u20134246","journal-title":"Cancer Res"},{"issue":"5","key":"2046_CR47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jpha.2023.04.010","volume":"13","author":"YQ Song","year":"2023","unstructured":"Song YQ et al (2023) A robust luminescent assay for screening alkyladenine DNA glycosylase inhibitors to overcome DNA repair and Temozolomide drug resistance. J Pharm Anal 13(5):514\u2013522","journal-title":"J Pharm Anal"},{"issue":"1","key":"2046_CR48","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1038\/s41467-019-13394-w","volume":"10","author":"NP Montaldo","year":"2019","unstructured":"Montaldo NP et al (2019) Alkyladenine DNA glycosylase associates with transcription elongation to coordinate DNA repair with gene expression. Nat Commun 10(1):5460","journal-title":"Nat Commun"},{"issue":"8","key":"2046_CR49","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/chem.201805555","volume":"25","author":"C Caron","year":"2019","unstructured":"Caron C et al (2019) Interaction of functionalized naphthalenophanes with Abasic sites in DNA: DNA cleavage, DNA cleavage Inhibition, and formation of Ligand-DNA adducts. Chemistry 25(8):1949\u20131962","journal-title":"Chemistry"},{"issue":"10","key":"2046_CR50","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/neuonc\/noae120","volume":"26","author":"B Golbourn","year":"2024","unstructured":"Golbourn B et al (2024) A Kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC\/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol 26(10):1895\u20131911","journal-title":"Neuro Oncol"},{"key":"2046_CR51","doi-asserted-by":"crossref","unstructured":"Cheng X et al (2024) Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma. Nat Commun 15(1):1957","DOI":"10.1038\/s41467-024-45979-5"},{"issue":"10","key":"2046_CR52","doi-asserted-by":"publisher","first-page":"e2118940119","DOI":"10.1073\/pnas.2118940119","volume":"119","author":"A Kumar","year":"2022","unstructured":"Kumar A et al (2022) Interlocking activities of DNA polymerase \u0392 in the base excision repair pathway. Proc Natl Acad Sci U S A 119(10):e2118940119","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2046_CR53","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/ars.2008.2194","volume":"11","author":"G Tell","year":"2009","unstructured":"Tell G et al (2009) The many functions of APE1\/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11(3):601\u2013620","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2046_CR54","doi-asserted-by":"publisher","first-page":"zcae034","DOI":"10.1093\/narcan\/zcae034","volume":"6","author":"A Bora","year":"2024","unstructured":"Bora A et al (2024) DNA Abasic sites act as rational therapeutic targets to synergize Temozolomide response in both MMR-proficient and deficient cancer. NAR Cancer 6(3):zcae034","journal-title":"NAR Cancer"},{"issue":"8","key":"2046_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41588-020-0669-3","volume":"52","author":"EA Bruford","year":"2020","unstructured":"Bruford EA et al (2020) Guidelines for human gene nomenclature. Nat Genet 52(8):754\u2013758","journal-title":"Nat Genet"},{"issue":"1","key":"2046_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gpb.2020.10.005","volume":"19","author":"Z Zhao","year":"2021","unstructured":"Zhao Z et al (2021) Chinese glioma genome atlas (CGGA): A comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteom Bioinf 19(1):1\u201312","journal-title":"Genomics Proteom Bioinf"},{"issue":"8","key":"2046_CR57","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"6","key":"2046_CR58","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s13311-022-01249-0","volume":"19","author":"HL Smith","year":"2022","unstructured":"Smith HL, Wadhwani N, Horbinski C (2022) Major features of the 2021 WHO classification of CNS tumors. Neurotherapeutics 19(6):1691\u20131704","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2046_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4143\/crt.2020.506","volume":"53","author":"L Lin","year":"2021","unstructured":"Lin L et al (2021) Mutant IDH1 enhances Temozolomide sensitivity via regulation of the ATM\/CHK2 pathway in glioma. Cancer Res Treat 53(2):367\u2013377","journal-title":"Cancer Res Treat"},{"key":"2046_CR60","doi-asserted-by":"crossref","unstructured":"Sun X, Turcan S (2021) From laboratory studies to clinical trials: Temozolomide use in IDH-Mutant gliomas. Cells, 10(5):1225","DOI":"10.3390\/cells10051225"},{"key":"2046_CR61","doi-asserted-by":"crossref","unstructured":"Kadiyala P et al (2021) Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Invest, 131(4):e139542","DOI":"10.1172\/JCI139542"},{"issue":"11","key":"2046_CR62","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-0226","volume":"10","author":"H Nagashima","year":"2020","unstructured":"Nagashima H et al (2020) Poly(ADP-ribose) glycohydrolase Inhibition sequesters NAD(+) to potentiate the metabolic lethality of alkylating chemotherapy in IDH-Mutant tumor cells. Cancer Discov 10(11):1672\u20131689","journal-title":"Cancer Discov"},{"issue":"6","key":"2046_CR63","first-page":"2189","volume":"54","author":"IM Forte","year":"2019","unstructured":"Forte IM et al (2019) Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to Temozolomide. Int J Oncol 54(6):2189\u20132199","journal-title":"Int J Oncol"},{"issue":"1","key":"2046_CR64","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1038\/s41467-024-49316-8","volume":"15","author":"DJ Laverty","year":"2024","unstructured":"Laverty DJ et al (2024) ATM Inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nat Commun 15(1):5294","journal-title":"Nat Commun"},{"key":"2046_CR65","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.canlet.2018.01.056","volume":"419","author":"B Han","year":"2018","unstructured":"Han B et al (2018) Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance Temozolomide sensitivity in glioma. Cancer Lett 419:280\u2013290","journal-title":"Cancer Lett"},{"issue":"6","key":"2046_CR66","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/neuonc\/noab292","volume":"24","author":"C Hu","year":"2022","unstructured":"Hu C et al (2022) ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro Oncol 24(6):888\u2013900","journal-title":"Neuro Oncol"},{"key":"2046_CR67","doi-asserted-by":"crossref","unstructured":"Amen AM et al (2021) Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proc Natl Acad Sci U S A, 118(13):e2008772118","DOI":"10.1073\/pnas.2008772118"},{"issue":"6","key":"2046_CR68","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/neuonc\/noae016","volume":"26","author":"MS Waitkus","year":"2024","unstructured":"Waitkus MS et al (2024) Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas. Neuro Oncol 26(6):1012\u20131024","journal-title":"Neuro Oncol"},{"issue":"12","key":"2046_CR69","doi-asserted-by":"publisher","first-page":"111344","DOI":"10.1016\/j.celrep.2022.111344","volume":"40","author":"AM McKinney","year":"2022","unstructured":"McKinney AM et al (2022) GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. Cell Rep 40(12):111344","journal-title":"Cell Rep"},{"issue":"12","key":"2046_CR70","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cac2.12502","volume":"43","author":"X Cui","year":"2023","unstructured":"Cui X et al (2023) Blockage of EGFR\/AKT and mevalonate pathways synergize the antitumor effect of Temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Commun (Lond) 43(12):1326\u20131353","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"2046_CR71","doi-asserted-by":"publisher","first-page":"188616","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS et al (2021) Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 1876(2):188616","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2046_CR72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","volume":"38","author":"R Vengoji","year":"2019","unstructured":"Vengoji R et al (2019) Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res 38(1):266","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2046_CR73","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41419-022-05044-9","volume":"13","author":"I de Souza","year":"2022","unstructured":"de Souza I et al (2022) High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation. Cell Death Dis 13(7):591","journal-title":"Cell Death Dis"},{"issue":"1","key":"2046_CR74","first-page":"vdaa001","volume":"2","author":"DS Nesterova","year":"2020","unstructured":"Nesterova DS et al (2020) Sexually dimorphic impact of the iron-regulating gene, HFE, on survival in glioblastoma. Neurooncol Adv 2(1):vdaa001","journal-title":"Neurooncol Adv"},{"key":"2046_CR75","doi-asserted-by":"crossref","unstructured":"McAleenan A et al (2021) Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with Temozolomide. Cochrane Database Syst Rev, 3(3): p. Cd013316.","DOI":"10.1002\/14651858.CD013316.pub2"},{"issue":"1","key":"2046_CR76","first-page":"vdae105","volume":"6","author":"T Haynes","year":"2024","unstructured":"Haynes T et al (2024) Pathways to hypermutation in high-grade gliomas: mechanisms, syndromes, and opportunities for immunotherapy. Neurooncol Adv 6(1):vdae105","journal-title":"Neurooncol Adv"},{"issue":"7785","key":"2046_CR77","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel FP et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576(7785):112\u2013120","journal-title":"Nature"},{"issue":"7804","key":"2046_CR78","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M et al (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580(7804):517\u2013523","journal-title":"Nature"},{"issue":"29","key":"2046_CR79","doi-asserted-by":"publisher","first-page":"e2400023","DOI":"10.1002\/advs.202400023","volume":"11","author":"C Xu","year":"2024","unstructured":"Xu C et al (2024) TRIM24 cooperates with Ras mutation to drive glioma progression through snorna recruitment of PHAX and DNA-PKcs. Adv Sci (Weinh) 11(29):e2400023","journal-title":"Adv Sci (Weinh)"},{"key":"2046_CR80","doi-asserted-by":"crossref","unstructured":"Huchede P et al (2024) BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas. Elife, 12","DOI":"10.7554\/eLife.91313"},{"issue":"4","key":"2046_CR81","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/nar\/gkac800","volume":"51","author":"LRZ Cohen","year":"2023","unstructured":"Cohen LRZ et al (2023) PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation. Nucleic Acids Res 51(4):1662\u20131673","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2046_CR82","first-page":"1519","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay R et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21(12):1519\u20131528","journal-title":"Neuro Oncol"},{"issue":"2","key":"2046_CR83","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11060-020-03528-2","volume":"148","author":"VM Lu","year":"2020","unstructured":"Lu VM et al (2020) The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neurooncol 148(2):221\u2013229","journal-title":"J Neurooncol"},{"issue":"739","key":"2046_CR84","doi-asserted-by":"publisher","first-page":"eadg5553","DOI":"10.1126\/scitranslmed.adg5553","volume":"16","author":"J Yin","year":"2024","unstructured":"Yin J et al (2024) Reactivating PTEN to impair glioma stem cells by inhibiting cytosolic iron-sulfur assembly. Sci Transl Med 16(739):eadg5553","journal-title":"Sci Transl Med"},{"issue":"25","key":"2046_CR85","doi-asserted-by":"publisher","first-page":"eabn3471","DOI":"10.1126\/sciadv.abn3471","volume":"8","author":"DM Tiek","year":"2022","unstructured":"Tiek DM et al (2022) Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas. Sci Adv 8(25):eabn3471","journal-title":"Sci Adv"},{"key":"2046_CR86","doi-asserted-by":"crossref","unstructured":"Uribe ML, Marrocco I, Yarden Y (2021) EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers (Basel), 13(11):2748","DOI":"10.3390\/cancers13112748"},{"issue":"11","key":"2046_CR87","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s12031-020-01779-2","volume":"71","author":"H Lu","year":"2021","unstructured":"Lu H, Liu P, Pang Q (2021) MiR-27a-3p\/miR-27b-3p promotes neurofibromatosis type 1 via targeting of NF1. J Mol Neurosci 71(11):2353\u20132363","journal-title":"J Mol Neurosci"},{"issue":"1","key":"2046_CR88","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13287-024-03827-9","volume":"15","author":"X Li","year":"2024","unstructured":"Li X et al (2024) Biological characteristics of tissue engineered-nerve grafts enhancing peripheral nerve regeneration. Stem Cell Res Ther 15(1):215","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2046_CR89","doi-asserted-by":"publisher","first-page":"9471","DOI":"10.1038\/s41598-020-65331-3","volume":"10","author":"C Zhao","year":"2020","unstructured":"Zhao C et al (2020) MicroRNA-128-3p enhances the chemosensitivity of Temozolomide in glioblastoma by targeting c-Met and EMT. Sci Rep 10(1):9471","journal-title":"Sci Rep"},{"issue":"1","key":"2046_CR90","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1038\/s41598-020-60218-9","volume":"10","author":"ZQ Liu","year":"2020","unstructured":"Liu ZQ et al (2020) MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7. Sci Rep 10(1):4155","journal-title":"Sci Rep"},{"key":"2046_CR91","doi-asserted-by":"publisher","first-page":"104390","DOI":"10.1016\/j.phrs.2019.104390","volume":"147","author":"KH Ho","year":"2019","unstructured":"Ho KH et al (2019) miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances Temozolomide cytotoxicity in glioblastoma multiforme. Pharmacol Res 147:104390","journal-title":"Pharmacol Res"},{"issue":"1","key":"2046_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12964-020-00587-w","volume":"18","author":"MH Pourhanifeh","year":"2020","unstructured":"Pourhanifeh MH et al (2020) Autophagy in cancers including brain tumors: role of MicroRNAs. Cell Commun Signal 18(1):88","journal-title":"Cell Commun Signal"},{"issue":"1","key":"2046_CR93","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1038\/s41598-022-11757-w","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y et al (2022) Cyanidin-3-O-glucoside inhibits the \u03b2-catenin\/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells. Sci Rep 12(1):7773","journal-title":"Sci Rep"},{"issue":"20","key":"2046_CR94","doi-asserted-by":"publisher","first-page":"11755","DOI":"10.1111\/jcmm.15788","volume":"24","author":"W Chen","year":"2020","unstructured":"Chen W et al (2020) LncRNA HOXA-AS3 promotes the malignancy of glioblastoma through regulating miR-455-5p\/USP3 axis. J Cell Mol Med 24(20):11755\u201311767","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2046_CR95","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jcmm.14829","volume":"24","author":"X Du","year":"2020","unstructured":"Du X et al (2020) LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511\/miR-524-5p\/YB1\/ZEB1 positive feedback loop. J Cell Mol Med 24(2):1474\u20131487","journal-title":"J Cell Mol Med"},{"key":"2046_CR96","doi-asserted-by":"publisher","first-page":"586653","DOI":"10.3389\/fphar.2020.586653","volume":"11","author":"H Zhu","year":"2020","unstructured":"Zhu H et al (2020) Long noncoding RNA LINC-PINT suppresses cell proliferation, invasion, and EMT by blocking Wnt\/\u03b2-Catenin signaling in glioblastoma. Front Pharmacol 11:586653","journal-title":"Front Pharmacol"},{"issue":"12","key":"2046_CR97","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/neuonc\/noaa127","volume":"22","author":"M Buccarelli","year":"2020","unstructured":"Buccarelli M et al (2020) Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of LncRNA MEG3. Neuro Oncol 22(12):1771\u20131784","journal-title":"Neuro Oncol"},{"issue":"8","key":"2046_CR98","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1111\/cas.15387","volume":"113","author":"J Zhou","year":"2022","unstructured":"Zhou J et al (2022) LncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K\/AKT pathway in glioma. Cancer Sci 113(8):2681\u20132692","journal-title":"Cancer Sci"},{"issue":"15","key":"2046_CR99","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1002\/cam4.4083","volume":"10","author":"T Yin","year":"2021","unstructured":"Yin T et al (2021) Long non-coding RNA HULC stimulates the epithelial-mesenchymal transition process and vasculogenic mimicry in human glioblastoma. Cancer Med 10(15):5270\u20135282","journal-title":"Cancer Med"},{"issue":"2","key":"2046_CR100","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11010-020-03937-x","volume":"476","author":"C Li","year":"2021","unstructured":"Li C, Feng S, Chen L (2021) MSC-AS1 knockdown inhibits cell growth and Temozolomide resistance by regulating miR-373-3p\/CPEB4 axis in glioma through PI3K\/Akt pathway. Mol Cell Biochem 476(2):699\u2013713","journal-title":"Mol Cell Biochem"},{"issue":"11","key":"2046_CR101","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41419-021-04245-y","volume":"12","author":"T Liu","year":"2021","unstructured":"Liu T et al (2021) A positive feedback loop of lncRNA-RMRP\/ZNRF3 axis and Wnt\/\u03b2-catenin signaling regulates the progression and Temozolomide resistance in glioma. Cell Death Dis 12(11):952","journal-title":"Cell Death Dis"},{"key":"2046_CR102","doi-asserted-by":"publisher","first-page":"560543","DOI":"10.3389\/fphar.2020.560543","volume":"11","author":"QL Lv","year":"2020","unstructured":"Lv QL et al (2020) Knockdown LncRNA DLEU1 inhibits gliomas progression and promotes Temozolomide chemosensitivity by regulating autophagy. Front Pharmacol 11:560543","journal-title":"Front Pharmacol"},{"issue":"2","key":"2046_CR103","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cas.15240","volume":"113","author":"KH Ho","year":"2022","unstructured":"Ho KH et al (2022) Hypoxia-inducible LncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy. Cancer Sci 113(2):540\u2013552","journal-title":"Cancer Sci"},{"key":"2046_CR104","doi-asserted-by":"crossref","unstructured":"Chen Q et al (2021) Over-expression of lncRNA TMEM161B-AS1 promotes the malignant biological behavior of glioma cells and the resistance to temozolomide via up-regulating the expression of multiple ferroptosis-related genes by sponging hsa-miR-27a-3p. Cell Death Discov, 7(1):311","DOI":"10.1038\/s41420-021-00709-4"},{"issue":"12","key":"2046_CR105","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/2326-6066.CIR-21-0258","volume":"9","author":"Z Li","year":"2021","unstructured":"Li Z et al (2021) Glioblastoma Cell-Derived lncRNA-Containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res 9(12):1383\u20131399","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2046_CR106","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1111\/cas.15072","volume":"112","author":"XD Li","year":"2021","unstructured":"Li XD et al (2021) Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic Glycolysis and Temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. Cancer Sci 112(11):4543\u20134552","journal-title":"Cancer Sci"},{"issue":"6","key":"2046_CR107","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10565-021-09614-z","volume":"38","author":"X Wang","year":"2022","unstructured":"Wang X et al (2022) Long non-coding RNA OIP5-AS1 Inhibition upregulates microRNA-129-5p to repress resistance to Temozolomide in glioblastoma cells via downregulating IGF2BP2. Cell Biol Toxicol 38(6):963\u2013977","journal-title":"Cell Biol Toxicol"},{"key":"2046_CR108","doi-asserted-by":"crossref","unstructured":"Li H et al (2021) Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. Cell Death Dis, 12(3):252","DOI":"10.1038\/s41419-021-03533-x"},{"issue":"20","key":"2046_CR109","doi-asserted-by":"publisher","first-page":"12094","DOI":"10.1111\/jcmm.15846","volume":"24","author":"C Wu","year":"2020","unstructured":"Wu C et al (2020) LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470\/miR-134\/Myc\/ABCC1 axis in glioma. J Cell Mol Med 24(20):12094\u201312106","journal-title":"J Cell Mol Med"},{"key":"2046_CR110","doi-asserted-by":"publisher","first-page":"109790","DOI":"10.1016\/j.neuropharm.2023.109790","volume":"243","author":"LY Jiang","year":"2024","unstructured":"Jiang LY et al (2024) CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBP\u03b1 binding. Neuropharmacology 243:109790","journal-title":"Neuropharmacology"},{"key":"2046_CR111","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fonc.2020.00170","volume":"10","author":"T Jin","year":"2020","unstructured":"Jin T et al (2020) Lcn2-derived circular RNA (hsa_circ_0088732) inhibits cell apoptosis and promotes EMT in glioma via the miR-661\/RAB3D Axis. Front Oncol 10:170","journal-title":"Front Oncol"},{"issue":"1","key":"2046_CR112","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s12035-024-04319-w","volume":"62","author":"W Yu","year":"2025","unstructured":"Yu W et al (2025) EIF4A3-Induced circ_0059914 promoted angiogenesis and EMT of glioma via the miR-1249\/VEGFA pathway. Mol Neurobiol 62(1):973\u2013987","journal-title":"Mol Neurobiol"},{"key":"2046_CR113","doi-asserted-by":"publisher","first-page":"1365032","DOI":"10.3389\/fonc.2024.1365032","volume":"14","author":"S Qiu","year":"2024","unstructured":"Qiu S et al (2024) Circular RNA PRKCI (hsa_circ_0067934): a potential target in the pathogenesis of human malignancies. Front Oncol 14:1365032","journal-title":"Front Oncol"},{"issue":"16","key":"2046_CR114","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.7150\/thno.95766","volume":"14","author":"L Liu","year":"2024","unstructured":"Liu L et al (2024) Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles. Theranostics 14(16):6392\u20136408","journal-title":"Theranostics"},{"issue":"1","key":"2046_CR115","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1080\/21655979.2021.2018096","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L et al (2022) Identification of a novel circular RNA circZNF652\/miR-486-5p\/SERPINE1 signaling cascade that regulates cancer aggressiveness in glioblastoma (GBM). Bioengineered 13(1):1411\u20131423","journal-title":"Bioengineered"},{"issue":"7","key":"2046_CR116","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41419-022-05056-5","volume":"13","author":"X Geng","year":"2022","unstructured":"Geng X et al (2022) Exosomal circWDR62 promotes Temozolomide resistance and malignant progression through regulation of the miR-370-3p\/MGMT axis in glioma. Cell Death Dis 13(7):596","journal-title":"Cell Death Dis"},{"issue":"9","key":"2046_CR117","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/cas.14517","volume":"111","author":"W Xu","year":"2020","unstructured":"Xu W et al (2020) MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci 111(9):3122\u20133131","journal-title":"Cancer Sci"},{"key":"2046_CR118","doi-asserted-by":"publisher","first-page":"637247","DOI":"10.3389\/fonc.2021.637247","volume":"11","author":"HS Kim","year":"2021","unstructured":"Kim HS et al (2021) Exosomal miR-125b exerts Anti-Metastatic properties and predicts early metastasis of hepatocellular carcinoma. Front Oncol 11:637247","journal-title":"Front Oncol"},{"key":"2046_CR119","doi-asserted-by":"crossref","unstructured":"Riemann A et al (2023) The role of MicroRNAs in gene expression and signaling response of tumor cells to an acidic environment. Int J Mol Sci, 24(23):16919","DOI":"10.3390\/ijms242316919"},{"key":"2046_CR120","doi-asserted-by":"publisher","first-page":"1390704","DOI":"10.3389\/fcell.2024.1390704","volume":"12","author":"AS Abdul Manap","year":"2024","unstructured":"Abdul Manap AS et al (2024) Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies. Front Cell Dev Biol 12:1390704","journal-title":"Front Cell Dev Biol"},{"key":"2046_CR121","doi-asserted-by":"crossref","unstructured":"Buruian\u0103 A et al (2020) The roles of MiRNA in glioblastoma tumor cell communication: diplomatic and aggressive negotiations. Int J Mol Sci, 21(6):1950","DOI":"10.3390\/ijms21061950"},{"key":"2046_CR122","doi-asserted-by":"crossref","unstructured":"Roscigno G et al (2020) miR-216a acts as a negative regulator of breast Cancer by modulating stemness properties and tumor microenvironment. Int J Mol Sci, 21(7):2313","DOI":"10.3390\/ijms21072313"},{"key":"2046_CR123","doi-asserted-by":"publisher","first-page":"109598","DOI":"10.1016\/j.cellsig.2020.109598","volume":"71","author":"P Cui","year":"2020","unstructured":"Cui P et al (2020) STAT3 Inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction. Cell Signal 71:109598","journal-title":"Cell Signal"},{"issue":"11","key":"2046_CR124","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1111\/cns.14277","volume":"29","author":"ZX Zhang","year":"2023","unstructured":"Zhang ZX et al (2023) HOXD-AS2-STAT3 feedback loop attenuates sensitivity to Temozolomide in glioblastoma. CNS Neurosci Ther 29(11):3430\u20133445","journal-title":"CNS Neurosci Ther"},{"issue":"20","key":"2046_CR125","doi-asserted-by":"publisher","first-page":"eade7236","DOI":"10.1126\/sciadv.ade7236","volume":"9","author":"EN Perrault","year":"2023","unstructured":"Perrault EN et al (2023) Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Sci Adv 9(20):eade7236","journal-title":"Sci Adv"},{"issue":"4","key":"2046_CR126","first-page":"1922","volume":"24","author":"JX Xu","year":"2020","unstructured":"Xu JX et al (2020) MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma. Eur Rev Med Pharmacol Sci 24(4):1922\u20131931","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2046_CR127","doi-asserted-by":"crossref","unstructured":"Chuang HY et al (2021) The E3 ubiquitin ligase NEDD4-1 mediates Temozolomide-Resistant glioblastoma through PTEN Attenuation and redox imbalance in Nrf2-HO-1 Axis. Int J Mol Sci, 22(19):10247","DOI":"10.3390\/ijms221910247"},{"issue":"8","key":"2046_CR128","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1111\/jcmm.15133","volume":"24","author":"S Kong","year":"2020","unstructured":"Kong S et al (2020) MiR-3116 sensitizes glioma cells to Temozolomide by targeting FGFR1 and regulating the FGFR1\/PI3K\/AKT pathway. J Cell Mol Med 24(8):4677\u20134686","journal-title":"J Cell Mol Med"},{"key":"2046_CR129","doi-asserted-by":"crossref","unstructured":"Zeng Z et al (2022) NcRNAs: Multi\u2013angle participation in the regulation of glioma chemotherapy resistance (Review). Int J Oncol, 60(6):76","DOI":"10.3892\/ijo.2022.5366"},{"issue":"4","key":"2046_CR130","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s12031-020-01706-5","volume":"71","author":"M Swellam","year":"2021","unstructured":"Swellam M et al (2021) Emerging role of MiRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. J Mol Neurosci 71(4):836\u2013844","journal-title":"J Mol Neurosci"},{"key":"2046_CR131","doi-asserted-by":"crossref","unstructured":"Li H et al (2024) Exosomal miR-423-5p Derived from Cerebrospinal Fluid Pulsation Stress-Stimulated Osteoblasts Improves Angiogenesis of Endothelial Cells via DUSP8\/ERK1\/2 Signaling Pathway. Stem Cells Int, 2024:5512423","DOI":"10.1155\/2024\/5512423"},{"issue":"1","key":"2046_CR132","doi-asserted-by":"publisher","first-page":"17768","DOI":"10.1038\/s41598-020-74746-x","volume":"10","author":"Z Areeb","year":"2020","unstructured":"Areeb Z et al (2020) Reduced EGFR and increased miR-221 is associated with increased resistance to Temozolomide and radiotherapy in glioblastoma. Sci Rep 10(1):17768","journal-title":"Sci Rep"},{"key":"2046_CR133","doi-asserted-by":"crossref","unstructured":"Yuan Y et al (2023) LncRNA CASC2 Regulate Cell Proliferation and Invasion by Targeting miR-155\/SOCS1 Axis in Hepatocellular Carcinoma. J Oncol, 2023: p. 8457112","DOI":"10.1155\/2023\/8457112"},{"issue":"8","key":"2046_CR134","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/abbs\/gmab066","volume":"53","author":"K Gao","year":"2021","unstructured":"Gao K et al (2021) miR-23b-5p promotes the chemosensitivity of Temozolomide via negatively regulating TLR4 in glioma. Acta Biochim Biophys Sin (Shanghai) 53(8):979\u2013987","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"3","key":"2046_CR135","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12015-024-10677-8","volume":"20","author":"S Li","year":"2024","unstructured":"Li S et al (2024) Extracellular vesicles derived from glioma stem cells affect glycometabolic reprogramming of glioma cells through the miR-10b-5p\/PTEN\/PI3K\/Akt pathway. Stem Cell Rev Rep 20(3):779\u2013796","journal-title":"Stem Cell Rev Rep"},{"issue":"5","key":"2046_CR136","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/glia.24506","volume":"72","author":"H Li","year":"2024","unstructured":"Li H et al (2024) Glioma stem cell-derived exosomes induce the transformation of astrocytes via the miR-3065-5p\/DLG2 signaling axis. Glia 72(5):857\u2013871","journal-title":"Glia"},{"issue":"11","key":"2046_CR137","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41419-020-03150-0","volume":"11","author":"P Wang","year":"2020","unstructured":"Wang P et al (2020) The HIF1\u03b1\/HIF2\u03b1-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions. Cell Death Dis 11(11):992","journal-title":"Cell Death Dis"},{"issue":"1","key":"2046_CR138","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1541-7786.MCR-20-0353","volume":"19","author":"T Cui","year":"2021","unstructured":"Cui T et al (2021) A novel miR-146a-POU3F2\/SMARCA5 pathway regulates stemness and therapeutic response in glioblastoma. Mol Cancer Res 19(1):48\u201360","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2046_CR139","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.gendis.2019.09.002","volume":"7","author":"X Guo","year":"2020","unstructured":"Guo X et al (2020) Identification of MiRNA signature associated with BMP2 and chemosensitivity of TMZ in glioblastoma stem-like cells. Genes Dis 7(3):424\u2013439","journal-title":"Genes Dis"},{"key":"2046_CR140","doi-asserted-by":"crossref","unstructured":"Su YK et al (2020) Targeting BC200\/miR218-5p signaling Axis for overcoming Temozolomide resistance and suppressing glioma stemness. Cells, 9(8):1859","DOI":"10.3390\/cells9081859"},{"issue":"19","key":"2046_CR141","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.7150\/thno.33800","volume":"9","author":"W Huang","year":"2019","unstructured":"Huang W et al (2019) The miR-26a\/AP-2\u03b1\/Nanog signaling axis mediates stem cell self-renewal and Temozolomide resistance in glioma. Theranostics 9(19):5497\u20135516","journal-title":"Theranostics"},{"issue":"1","key":"2046_CR142","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/21655979.2019.1710925","volume":"11","author":"L Chen","year":"2020","unstructured":"Chen L et al (2020) MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-\u03b21. Bioengineered 11(1):91\u2013102","journal-title":"Bioengineered"},{"issue":"3","key":"2046_CR143","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5607\/en20060","volume":"30","author":"R Gong","year":"2021","unstructured":"Gong R et al (2021) Long noncoding RNA PVT1 promotes stemness and Temozolomide resistance through miR-365\/ELF4\/SOX2 Axis in glioma. Exp Neurobiol 30(3):244\u2013255","journal-title":"Exp Neurobiol"},{"issue":"1","key":"2046_CR144","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yexcr.2018.12.016","volume":"375","author":"B Jia","year":"2019","unstructured":"Jia B et al (2019) MiR-7-5p suppresses stemness and enhances Temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res 375(1):73\u201381","journal-title":"Exp Cell Res"},{"issue":"767","key":"2046_CR145","doi-asserted-by":"publisher","first-page":"eado1573","DOI":"10.1126\/scitranslmed.ado1573","volume":"16","author":"X Liao","year":"2024","unstructured":"Liao X et al (2024) Dynamic structural remodeling of LINC01956 enhances Temozolomide resistance in MGMT-methylated glioblastoma. Sci Transl Med 16(767):eado1573","journal-title":"Sci Transl Med"},{"issue":"3","key":"2046_CR146","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ncrna.2024.03.010","volume":"9","author":"Y Zuo","year":"2024","unstructured":"Zuo Y et al (2024) Long non-coding RNA LIP interacts with PARP-1 influencing the efficiency of base excision repair. Noncoding RNA Res 9(3):649\u2013658","journal-title":"Noncoding RNA Res"},{"issue":"1","key":"2046_CR147","doi-asserted-by":"publisher","first-page":"26224","DOI":"10.1038\/s41598-024-77348-z","volume":"14","author":"T Lan","year":"2024","unstructured":"Lan T et al (2024) High expression of LncRNA HOTAIR is a risk factor for Temozolomide resistance in glioblastoma via activation of the miR-214\/\u03b2-catenin\/MGMT pathway. Sci Rep 14(1):26224","journal-title":"Sci Rep"},{"issue":"10","key":"2046_CR148","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1111\/jcmm.15233","volume":"24","author":"J Zhang","year":"2020","unstructured":"Zhang J et al (2020) HOTAIR\/miR-125 axis-mediated hexokinase 2 expression promotes chemoresistance in human glioblastoma. J Cell Mol Med 24(10):5707\u20135717","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2046_CR149","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41419-022-04699-8","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X et al (2022) Serum-derived extracellular vesicles facilitate Temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism. Cell Death Dis 13(4):344","journal-title":"Cell Death Dis"},{"key":"2046_CR150","doi-asserted-by":"publisher","first-page":"216812","DOI":"10.1016\/j.canlet.2024.216812","volume":"588","author":"E Yang","year":"2024","unstructured":"Yang E et al (2024) EPIC-0628 abrogates HOTAIR\/EZH2 interaction and enhances the Temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma. Cancer Lett 588:216812","journal-title":"Cancer Lett"},{"issue":"2","key":"2046_CR151","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1101\/gr.251058.119","volume":"30","author":"L Zhang","year":"2020","unstructured":"Zhang L et al (2020) A HOTAIR regulatory element modulates glioma cell sensitivity to Temozolomide through long-range regulation of multiple target genes. Genome Res 30(2):155\u2013163","journal-title":"Genome Res"},{"issue":"6","key":"2046_CR152","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4196\/kjpp.2019.23.6.475","volume":"23","author":"W Shangguan","year":"2019","unstructured":"Shangguan W, Lv X, Tian N (2019) FoxD2-AS1 is a prognostic factor in glioma and promotes Temozolomide resistance in a O(6)-methylguanine-DNA methyltransferase-dependent manner. Korean J Physiol Pharmacol 23(6):475\u2013482","journal-title":"Korean J Physiol Pharmacol"},{"issue":"22","key":"2046_CR153","doi-asserted-by":"publisher","first-page":"10266","DOI":"10.18632\/aging.102455","volume":"11","author":"N Gu","year":"2019","unstructured":"Gu N et al (2019) Silencing LncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p\/CPEB4 axis. Aging 11(22):10266\u201310283","journal-title":"Aging"},{"issue":"1","key":"2046_CR154","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1080\/21691401.2019.1671431","volume":"47","author":"Q Zhang","year":"2019","unstructured":"Zhang Q et al (2019) Long non-coding RNA LINC00473 promotes glioma cells proliferation and invasion by impairing miR-637\/CDK6 axis. Artif Cells Nanomed Biotechnol 47(1):3896\u20133903","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"5","key":"2046_CR155","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41419-020-2540-y","volume":"11","author":"B Liu","year":"2020","unstructured":"Liu B et al (2020) LncRNA SOX2OT promotes Temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. Cell Death Dis 11(5):384","journal-title":"Cell Death Dis"},{"issue":"6","key":"2046_CR156","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.7150\/ijbs.80873","volume":"19","author":"X Jiang","year":"2023","unstructured":"Jiang X et al (2023) LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression. Int J Biol Sci 19(6):1681\u20131697","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2046_CR157","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12885-023-10937-9","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen Y et al (2023) LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma. BMC Cancer 23(1):455","journal-title":"BMC Cancer"},{"issue":"1","key":"2046_CR158","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s13046-022-02431-0","volume":"41","author":"Z Gao","year":"2022","unstructured":"Gao Z et al (2022) PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C\/EBP\u03b2 degradation to facilitate proneural-to-mesenchymal transition. J Exp Clin Cancer Res 41(1):223","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2046_CR159","doi-asserted-by":"publisher","first-page":"e1010820","DOI":"10.1371\/journal.ppat.1010820","volume":"18","author":"X You","year":"2022","unstructured":"You X et al (2022) MiRNA let-7 family regulated by NEAT1 and ARID3A\/NF-\u03baB inhibits PRRSV-2 replication in vitro and in vivo. PLoS Pathog 18(10):e1010820","journal-title":"PLoS Pathog"},{"key":"2046_CR160","doi-asserted-by":"publisher","first-page":"p3941952","DOI":"10.1155\/2022\/3941952","volume":"2022","author":"L Lin","year":"2022","unstructured":"Lin L et al (2022) LncRNA HOXA-AS2 promotes Temozolomide resistance in glioblastoma by regulated miR-302a-3p\/IGF1 Axis. Genet Res (Camb) 2022:p3941952","journal-title":"Genet Res (Camb)"},{"issue":"6","key":"2046_CR161","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/08923973.2021.1966031","volume":"43","author":"T Fu","year":"2021","unstructured":"Fu T et al (2021) Silencing LncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to Temozolomide in glioblastoma cells by inactivating PTEN\/AKT pathway via targeting miR-370-3p. Immunopharmacol Immunotoxicol 43(6):680\u2013692","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"9","key":"2046_CR162","doi-asserted-by":"publisher","first-page":"e22848","DOI":"10.1002\/jbt.22848","volume":"35","author":"Y Lu","year":"2021","unstructured":"Lu Y et al (2021) LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt\/\u03b2-catenin signaling. J Biochem Mol Toxicol 35(9):e22848","journal-title":"J Biochem Mol Toxicol"},{"issue":"6","key":"2046_CR163","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10571-020-00898-z","volume":"41","author":"X He","year":"2021","unstructured":"He X et al (2021) LncRNA MIR155HG promotes Temozolomide resistance by activating the Wnt\/\u03b2-Catenin pathway via binding to PTBP1 in glioma. Cell Mol Neurobiol 41(6):1271\u20131284","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"2046_CR164","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei M et al (2020) Translation and functional roles of circular RNAs in human cancer. Mol Cancer 19(1):30","journal-title":"Mol Cancer"},{"issue":"1","key":"2046_CR165","first-page":"62","volume":"38","author":"G Li","year":"2023","unstructured":"Li G, Lan Q (2023) Exosome-Mediated transfer of circ-GLIS3 enhances Temozolomide resistance in glioma cells through the miR-548m\/MED31 Axis. Cancer Biother Radiopharm 38(1):62\u201373","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2046_CR166","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13046-021-01942-6","volume":"40","author":"C Ding","year":"2021","unstructured":"Ding C et al (2021) Warburg effect-promoted Exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances Temozolomide resistance in glioma. J Exp Clin Cancer Res 40(1):164","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2046_CR167","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1111\/cas.14984","volume":"112","author":"J Si","year":"2021","unstructured":"Si J et al (2021) Heparanase confers Temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. Cancer Sci 112(9):3491\u20133506","journal-title":"Cancer Sci"},{"issue":"7","key":"2046_CR168","first-page":"537","volume":"36","author":"C Han","year":"2021","unstructured":"Han C et al (2021) Exosomal circ-HIPK3 facilitates tumor progression and Temozolomide resistance by regulating miR-421\/ZIC5 Axis in glioma. Cancer Biother Radiopharm 36(7):537\u2013548","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2046_CR169","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12951-023-01801-w","volume":"21","author":"X Liu","year":"2023","unstructured":"Liu X et al (2023) Exosome-transmitted circCABIN1 promotes Temozolomide resistance in glioblastoma via sustaining erbb downstream signaling. J Nanobiotechnol 21(1):45","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"2046_CR170","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/10985549.2023.2210032","volume":"43","author":"J Li","year":"2023","unstructured":"Li J et al (2023) CircTTLL13 promotes TMZ resistance in glioma via modulating OLR1-Mediated activation of the Wnt\/\u03b2-Catenin pathway. Mol Cell Biol 43(7):354\u2013369","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2046_CR171","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s11011-022-01069-3","volume":"37","author":"X Li","year":"2022","unstructured":"Li X et al (2022) Hsa_circ_0043949 reinforces Temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. Metab Brain Dis 37(8):2979\u20132993","journal-title":"Metab Brain Dis"},{"issue":"4","key":"2046_CR172","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/neuonc\/noaa214","volume":"23","author":"Y Wei","year":"2021","unstructured":"Wei Y et al (2021) EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and Temozolomide resistance of glioblastoma via NRAS\/MEK1\/ERK1-2 signaling. Neuro Oncol 23(4):611\u2013624","journal-title":"Neuro Oncol"},{"key":"2046_CR173","doi-asserted-by":"publisher","first-page":"1004221","DOI":"10.3389\/fnmol.2022.1004221","volume":"15","author":"ZY Wang","year":"2022","unstructured":"Wang ZY et al (2022) Exosomal noncoding RNAs in central nervous system diseases: biological functions and potential clinical applications. Front Mol Neurosci 15:1004221","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"2046_CR174","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0192623320968181","volume":"49","author":"J Woicke","year":"2021","unstructured":"Woicke J et al (2021) International harmonization of nomenclature and diagnostic criteria (INHAND): nonproliferative and proliferative lesions of the dog. Toxicol Pathol 49(1):5\u2013109","journal-title":"Toxicol Pathol"},{"issue":"2","key":"2046_CR175","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s12035-024-04316-z","volume":"62","author":"P Goleij","year":"2025","unstructured":"Goleij P et al (2025) Role of Non-coding RNAs in the response of glioblastoma to Temozolomide. Mol Neurobiol 62(2):1726\u20131755","journal-title":"Mol Neurobiol"},{"issue":"4","key":"2046_CR176","doi-asserted-by":"publisher","first-page":"e14500","DOI":"10.1111\/cns.14500","volume":"30","author":"B Zhang","year":"2024","unstructured":"Zhang B et al (2024) The regulatory role and clinical application prospects of circrna in the occurrence and development of CNS tumors. CNS Neurosci Ther 30(4):e14500","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"2046_CR177","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/cns.13821","volume":"28","author":"F Yuan","year":"2022","unstructured":"Yuan F et al (2022) Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma. CNS Neurosci Ther 28(6):897\u2013912","journal-title":"CNS Neurosci Ther"},{"key":"2046_CR178","doi-asserted-by":"crossref","unstructured":"Biserova K et al (2021) Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma. Cells, 10(3):621","DOI":"10.3390\/cells10030621"},{"key":"2046_CR179","doi-asserted-by":"crossref","unstructured":"Huang M et al (2020) Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci Transl Med, 12(532):eaay7522","DOI":"10.1126\/scitranslmed.aay7522"},{"issue":"1","key":"2046_CR180","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","volume":"11","author":"CP Couturier","year":"2020","unstructured":"Couturier CP et al (2020) Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun 11(1):3406","journal-title":"Nat Commun"},{"issue":"7","key":"2046_CR181","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ccell.2024.06.004","volume":"42","author":"J Liu","year":"2024","unstructured":"Liu J et al (2024) Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell 42(7):1217\u20131238e19","journal-title":"Cancer Cell"},{"issue":"1","key":"2046_CR182","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.devcel.2021.12.007","volume":"57","author":"XP Xie","year":"2022","unstructured":"Xie XP et al (2022) Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. Dev Cell 57(1):32\u201346e8","journal-title":"Dev Cell"},{"key":"2046_CR183","doi-asserted-by":"publisher","first-page":"102773","DOI":"10.1016\/j.redox.2023.102773","volume":"64","author":"M Peleli","year":"2023","unstructured":"Peleli M et al (2023) Cystathionine gamma-lyase (CTH) Inhibition attenuates glioblastoma formation. Redox Biol 64:102773","journal-title":"Redox Biol"},{"issue":"1","key":"2046_CR184","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M et al (2023) Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Mol Cancer 22(1):189","journal-title":"Mol Cancer"},{"issue":"9","key":"2046_CR185","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41418-022-00969-2","volume":"29","author":"K Liu","year":"2022","unstructured":"Liu K et al (2022) Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation. Cell Death Differ 29(9):1834\u20131849","journal-title":"Cell Death Differ"},{"key":"2046_CR186","doi-asserted-by":"crossref","unstructured":"Zhu Y et al (2024) PDCD10 is a key player in TMZ-Resistance and tumor cell regrowth: insights into its underlying mechanism in glioblastoma cells. Cells, 13(17):1442","DOI":"10.3390\/cells13171442"},{"issue":"4","key":"2046_CR187","doi-asserted-by":"publisher","first-page":"113988","DOI":"10.1016\/j.celrep.2024.113988","volume":"43","author":"E Kuzmin","year":"2024","unstructured":"Kuzmin E et al (2024) Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring. Cell Rep 43(4):113988","journal-title":"Cell Rep"},{"issue":"34","key":"2046_CR188","doi-asserted-by":"publisher","first-page":"e2201609","DOI":"10.1002\/advs.202201609","volume":"9","author":"Q Yang","year":"2022","unstructured":"Yang Q et al (2022) Extracellular vesicles in Cancer drug resistance: roles, mechanisms, and implications. Adv Sci (Weinh) 9(34):e2201609","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2046_CR189","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12964-024-01819-z","volume":"22","author":"F Giammello","year":"2024","unstructured":"Giammello F et al (2024) Modulating voltage-gated sodium channels to enhance differentiation and sensitize glioblastoma cells to chemotherapy. Cell Commun Signal 22(1):434","journal-title":"Cell Commun Signal"},{"issue":"33","key":"2046_CR190","doi-asserted-by":"publisher","first-page":"e2303561","DOI":"10.1002\/advs.202303561","volume":"10","author":"S Li","year":"2023","unstructured":"Li S et al (2023) FBXO7 confers mesenchymal properties and chemoresistance in glioblastoma by controlling Rbfox2-Mediated alternative splicing. Adv Sci (Weinh) 10(33):e2303561","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"2046_CR191","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/0008-5472.CAN-21-2161","volume":"82","author":"J Auzmendi-Iriarte","year":"2022","unstructured":"Auzmendi-Iriarte J et al (2022) Chaperone-Mediated autophagy controls proteomic and transcriptomic pathways to maintain glioma stem cell activity. Cancer Res 82(7):1283\u20131297","journal-title":"Cancer Res"},{"key":"2046_CR192","doi-asserted-by":"crossref","unstructured":"Corrigendum (2023) to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5. Neuro Oncol, 25(10): p. 1913","DOI":"10.1093\/neuonc\/noad135"},{"issue":"1","key":"2046_CR193","doi-asserted-by":"publisher","first-page":"101255","DOI":"10.1016\/j.tranon.2021.101255","volume":"15","author":"KH Noh","year":"2022","unstructured":"Noh KH et al (2022) Novel cancer stem cell marker MVP enhances temozolomide-resistance in glioblastoma. Transl Oncol 15(1):101255","journal-title":"Transl Oncol"},{"issue":"19","key":"2046_CR194","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/0008-5472.CAN-21-3882","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) TRAF4 maintains deubiquitination of Caveolin-1 to drive glioblastoma stemness and Temozolomide resistance. Cancer Res 82(19):3573\u20133587","journal-title":"Cancer Res"},{"issue":"26","key":"2046_CR195","doi-asserted-by":"publisher","first-page":"e2202216","DOI":"10.1002\/advs.202202216","volume":"9","author":"Y Wei","year":"2022","unstructured":"Wei Y et al (2022) The interaction between DNMT1 and High-Mannose CD133 maintains the Slow-Cycling state and tumorigenic potential of glioma stem cell. Adv Sci (Weinh) 9(26):e2202216","journal-title":"Adv Sci (Weinh)"},{"key":"2046_CR196","doi-asserted-by":"publisher","first-page":"123132","DOI":"10.1016\/j.lfs.2024.123132","volume":"358","author":"K Somrit","year":"2024","unstructured":"Somrit K et al (2024) KHDRBS3 facilitates self-renewal and Temozolomide resistance of glioblastoma cell lines. Life Sci 358:123132","journal-title":"Life Sci"},{"issue":"11","key":"2046_CR197","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1172\/JCI127916","volume":"130","author":"BS Moon","year":"2020","unstructured":"Moon BS et al (2020) Epigenetic modulator Inhibition overcomes Temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma. J Clin Invest 130(11):5782\u20135799","journal-title":"J Clin Invest"},{"issue":"11","key":"2046_CR198","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.7150\/thno.41450","volume":"10","author":"I L\u00f3pez-Valero","year":"2020","unstructured":"L\u00f3pez-Valero I et al (2020) Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells. Theranostics 10(11):5120\u20135136","journal-title":"Theranostics"},{"issue":"9","key":"2046_CR199","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-20-0468","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu J et al (2022) Disruption of DNA repair and survival pathways through heat shock protein Inhibition by onalespib to sensitize malignant gliomas to chemoradiation therapy. Clin Cancer Res 28(9):1979\u20131990","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2046_CR200","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/neuonc\/noaa103","volume":"22","author":"WB Yang","year":"2020","unstructured":"Yang WB et al (2020) Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. Neuro Oncol 22(10):1439\u20131451","journal-title":"Neuro Oncol"},{"issue":"679","key":"2046_CR201","doi-asserted-by":"publisher","first-page":"eabq6288","DOI":"10.1126\/scitranslmed.abq6288","volume":"15","author":"KM Eyme","year":"2023","unstructured":"Eyme KM et al (2023) Targeting de Novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models. Sci Transl Med 15(679):eabq6288","journal-title":"Sci Transl Med"},{"issue":"7","key":"2046_CR202","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/neuonc\/noad018","volume":"25","author":"S Alejo","year":"2023","unstructured":"Alejo S et al (2023) Lysine-specific histone demethylase 1A (KDM1A\/LSD1) Inhibition attenuates DNA double-strand break repair and augments the efficacy of Temozolomide in glioblastoma. Neuro Oncol 25(7):1249\u20131261","journal-title":"Neuro Oncol"},{"key":"2046_CR203","doi-asserted-by":"crossref","unstructured":"Fedele M et al (2019) Proneural-Mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci, 20(11):2746","DOI":"10.3390\/ijms20112746"},{"issue":"1","key":"2046_CR204","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41467-023-44572-6","volume":"15","author":"Z Luo","year":"2024","unstructured":"Luo Z et al (2024) Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun 15(1):255","journal-title":"Nat Commun"},{"issue":"23","key":"2046_CR205","doi-asserted-by":"publisher","first-page":"eadj7706","DOI":"10.1126\/sciadv.adj7706","volume":"10","author":"JH Park","year":"2024","unstructured":"Park JH et al (2024) Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells. Sci Adv 10(23):eadj7706","journal-title":"Sci Adv"},{"issue":"4","key":"2046_CR206","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.7150\/thno.47057","volume":"11","author":"J Yin","year":"2021","unstructured":"Yin J et al (2021) Extracellular vesicles derived from hypoxic glioma stem-like cells confer Temozolomide resistance on glioblastoma by delivering miR-30b-3p. Theranostics 11(4):1763\u20131779","journal-title":"Theranostics"},{"issue":"1","key":"2046_CR207","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13046-021-02031-4","volume":"40","author":"M Buccarelli","year":"2021","unstructured":"Buccarelli M et al (2021) Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J Exp Clin Cancer Res 40(1):228","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2046_CR208","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","volume":"9","author":"RK Amaravadi","year":"2019","unstructured":"Amaravadi RK, Kimmelman AC, Debnath J (2019) Targeting autophagy in cancer: recent advances and future directions. Cancer Discov 9(9):1167\u20131181","journal-title":"Cancer Discov"},{"issue":"1","key":"2046_CR209","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12964-023-01108-1","volume":"21","author":"S Wan","year":"2023","unstructured":"Wan S et al (2023) Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. Cell Commun Signal 21(1):115","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2046_CR210","doi-asserted-by":"publisher","first-page":"e22973","DOI":"10.1002\/jbt.22973","volume":"36","author":"YY Xue","year":"2022","unstructured":"Xue YY et al (2022) CN-3 increases TMZ sensitivity and induces ROS-dependent apoptosis and autophagy in TMZ-resistance glioblastoma. J Biochem Mol Toxicol 36(3):e22973","journal-title":"J Biochem Mol Toxicol"},{"issue":"10","key":"2046_CR211","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1016\/j.apsb.2022.06.004","volume":"12","author":"L Zou","year":"2022","unstructured":"Zou L et al (2022) Autophagy and beyond: unraveling the complexity of UNC-51-like kinase 1 (ULK1) from biological functions to therapeutic implications. Acta Pharm Sin B 12(10):3743\u20133782","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"2046_CR212","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00253-019-10257-8","volume":"104","author":"Z Xu","year":"2020","unstructured":"Xu Z et al (2020) Targeting PI3K\/AKT\/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol 104(2):575\u2013587","journal-title":"Appl Microbiol Biotechnol"},{"key":"2046_CR213","doi-asserted-by":"crossref","unstructured":"Hwang YK et al (2024) Importance of autophagy regulation in glioblastoma with Temozolomide resistance. Cells, 13(16):1332","DOI":"10.3390\/cells13161332"},{"key":"2046_CR214","doi-asserted-by":"publisher","first-page":"1297506","DOI":"10.3389\/fimmu.2023.1297506","volume":"14","author":"LQ Yang","year":"2023","unstructured":"Yang LQ, Huang AF, Xu WD (2023) Biology of endophilin and it\u2019s role in disease. Front Immunol 14:1297506","journal-title":"Front Immunol"},{"issue":"1","key":"2046_CR215","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13046-022-02429-8","volume":"41","author":"CH Chien","year":"2022","unstructured":"Chien CH et al (2022) SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against Temozolomide in glioblastoma. J Exp Clin Cancer Res 41(1):220","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2046_CR216","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41419-020-02988-8","volume":"11","author":"EJ Yun","year":"2020","unstructured":"Yun EJ et al (2020) Wnt\/\u03b2-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis 11(9):771","journal-title":"Cell Death Dis"},{"issue":"1","key":"2046_CR217","doi-asserted-by":"publisher","first-page":"e70168","DOI":"10.1111\/cns.70168","volume":"31","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) ADAR1 promotes the progression and Temozolomide resistance of glioma through p62-Mediated selective autophagy. CNS Neurosci Ther 31(1):e70168","journal-title":"CNS Neurosci Ther"},{"key":"2046_CR218","doi-asserted-by":"publisher","first-page":"1397863","DOI":"10.3389\/fonc.2024.1397863","volume":"14","author":"M Luo","year":"2024","unstructured":"Luo M et al (2024) Revisiting the potential of regulated cell death in glioma treatment: a focus on autophagy-dependent cell death, Anoikis, ferroptosis, Cuproptosis, pyroptosis, Immunogenic cell death, and the crosstalk between them. Front Oncol 14:1397863","journal-title":"Front Oncol"},{"issue":"1","key":"2046_CR219","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-020-1138-4","volume":"19","author":"X Li","year":"2020","unstructured":"Li X, He S, Ma B (2020) Autophagy and autophagy-related proteins in cancer. Mol Cancer 19(1):12","journal-title":"Mol Cancer"},{"key":"2046_CR220","doi-asserted-by":"publisher","first-page":"1327621","DOI":"10.3389\/fncel.2023.1327621","volume":"17","author":"M Chiariello","year":"2023","unstructured":"Chiariello M et al (2023) Overcoming challenges in glioblastoma treatment: targeting infiltrating cancer cells and Harnessing the tumor microenvironment. Front Cell Neurosci 17:1327621","journal-title":"Front Cell Neurosci"},{"issue":"27","key":"2046_CR221","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth D, Wang YA (2023) Glioblastoma heterogeneity at single cell resolution. Oncogene 42(27):2155\u20132165","journal-title":"Oncogene"},{"key":"2046_CR222","doi-asserted-by":"publisher","first-page":"1238233","DOI":"10.3389\/fimmu.2023.1238233","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Front Immunol 14:1238233","journal-title":"Front Immunol"},{"key":"2046_CR223","doi-asserted-by":"publisher","first-page":"156271","DOI":"10.1016\/j.phymed.2024.156271","volume":"136","author":"H Zhang","year":"2025","unstructured":"Zhang H et al (2025) Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG\/CCL2 axis. Phytomedicine 136:156271","journal-title":"Phytomedicine"},{"issue":"1","key":"2046_CR224","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","volume":"43","author":"W Yang","year":"2024","unstructured":"Yang W et al (2024) T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. J Exp Clin Cancer Res 43(1):38","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2046_CR225","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","volume":"41","author":"M Bausart","year":"2022","unstructured":"Bausart M, Pr\u00e9at V, Malfanti A (2022) Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 41(1):35","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2046_CR226","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12967-022-03813-w","volume":"20","author":"M Liu","year":"2022","unstructured":"Liu M et al (2022) Targeting macrophages: a novel treatment strategy in solid tumors. J Transl Med 20(1):586","journal-title":"J Transl Med"},{"issue":"1","key":"2046_CR227","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","volume":"10","author":"S Zhu","year":"2021","unstructured":"Zhu S et al (2021) Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol 10(1):60","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2046_CR228","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12967-021-03003-0","volume":"19","author":"J Liu","year":"2021","unstructured":"Liu J et al (2021) BCL7A as a novel prognostic biomarker for glioma patients. J Transl Med 19(1):335","journal-title":"J Transl Med"},{"issue":"3","key":"2046_CR229","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.7150\/thno.50150","volume":"11","author":"MN Hasan","year":"2021","unstructured":"Hasan MN et al (2021) Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics 11(3):1295\u20131309","journal-title":"Theranostics"},{"key":"2046_CR230","doi-asserted-by":"publisher","first-page":"834595","DOI":"10.3389\/fimmu.2022.834595","volume":"13","author":"Z Xu","year":"2022","unstructured":"Xu Z et al (2022) Matrix Remodeling-Associated protein 8 as a novel Indicator contributing to glioma immune response by regulating ferroptosis. Front Immunol 13:834595","journal-title":"Front Immunol"},{"key":"2046_CR231","doi-asserted-by":"publisher","first-page":"122708","DOI":"10.1016\/j.biomaterials.2024.122708","volume":"311","author":"J Li","year":"2024","unstructured":"Li J et al (2024) Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Biomaterials 311:122708","journal-title":"Biomaterials"},{"issue":"18","key":"2046_CR232","doi-asserted-by":"publisher","first-page":"e2300679","DOI":"10.1002\/advs.202300679","volume":"10","author":"Y Liu","year":"2023","unstructured":"Liu Y et al (2023) In situ nitric oxide gas nanogenerator reprograms glioma immunosuppressive microenvironment. Adv Sci (Weinh) 10(18):e2300679","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2046_CR233","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-023-02686-1","volume":"42","author":"F Liu","year":"2023","unstructured":"Liu F et al (2023) Piperlongumine conquers Temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8(+)-T cell immunity. J Exp Clin Cancer Res 42(1):118","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2046_CR234","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12951-024-02376-w","volume":"22","author":"X Li","year":"2024","unstructured":"Li X et al (2024) Glioma-targeted Oxaliplatin\/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe(2+) and boosting Fenton reaction. J Nanobiotechnol 22(1):93","journal-title":"J Nanobiotechnol"},{"key":"2046_CR235","doi-asserted-by":"crossref","unstructured":"Phon BWS et al (2025) Revisiting ABC transporters and their clinical significance in glioblastoma. Pharmaceuticals (Basel), 18(1):102","DOI":"10.3390\/ph18010102"},{"key":"2046_CR236","doi-asserted-by":"publisher","first-page":"106510","DOI":"10.1016\/j.phrs.2022.106510","volume":"185","author":"L Radtke","year":"2022","unstructured":"Radtke L et al (2022) CRISPR\/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. Pharmacol Res 185:106510","journal-title":"Pharmacol Res"},{"issue":"8","key":"2046_CR237","first-page":"3892","volume":"12","author":"Z Chen","year":"2022","unstructured":"Chen Z et al (2022) Prrx1 promotes resistance to Temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma. Am J Cancer Res 12(8):3892\u20133912","journal-title":"Am J Cancer Res"},{"key":"2046_CR238","doi-asserted-by":"crossref","unstructured":"Khunweeraphong N, Kuchler K (2021) Multidrug resistance in mammals and Fungi-From MDR to PDR: A Rocky road from atomic structures to transport mechanisms. Int J Mol Sci, 22(9):4806","DOI":"10.3390\/ijms22094806"},{"issue":"10","key":"2046_CR239","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","volume":"23","author":"HW Sim","year":"2021","unstructured":"Sim HW et al (2021) A randomized phase II trial of veliparib, radiotherapy, and Temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol 23(10):1736\u20131749","journal-title":"Neuro Oncol"},{"issue":"17","key":"2046_CR240","doi-asserted-by":"publisher","first-page":"1900782","DOI":"10.1002\/advs.201900782","volume":"6","author":"K Huang","year":"2019","unstructured":"Huang K et al (2019) Genome-Wide CRISPR-Cas9 screening identifies NF-\u03baB\/E2F6 responsible for EGFRvIII-Associated Temozolomide resistance in glioblastoma. Adv Sci (Weinh) 6(17):1900782","journal-title":"Adv Sci (Weinh)"},{"issue":"15","key":"2046_CR241","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.7150\/thno.45688","volume":"10","author":"L Wang","year":"2020","unstructured":"Wang L et al (2020) Homotrimer cavin1 interacts with caveolin1 to facilitate tumor growth and activate microglia through extracellular vesicles in glioma. Theranostics 10(15):6674\u20136694","journal-title":"Theranostics"},{"issue":"9","key":"2046_CR242","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.7150\/thno.71763","volume":"12","author":"E Yang","year":"2022","unstructured":"Yang E et al (2022) PTRF\/Cavin-1 enhances chemo-resistance and promotes Temozolomide efflux through extracellular vesicles in glioblastoma. Theranostics 12(9):4330\u20134347","journal-title":"Theranostics"},{"issue":"1","key":"2046_CR243","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH et al (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20(1):12\u201325","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"2046_CR244","doi-asserted-by":"publisher","first-page":"e103790","DOI":"10.15252\/embj.2019103790","volume":"39","author":"AA Dumas","year":"2020","unstructured":"Dumas AA et al (2020) Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. Embo J 39(15):e103790","journal-title":"Embo J"},{"issue":"10","key":"2046_CR245","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K (2020) Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem 20(10):815\u2013834","journal-title":"Curr Top Med Chem"},{"key":"2046_CR246","doi-asserted-by":"crossref","unstructured":"Ezzati S et al (2024) Epidermal growth factor receptor inhibitors in glioblastoma: current status and future possibilities. Int J Mol Sci, 25(4):2316","DOI":"10.3390\/ijms25042316"},{"key":"2046_CR247","doi-asserted-by":"publisher","first-page":"1145300","DOI":"10.3389\/fimmu.2023.1145300","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X et al (2023) Integrating single-cell RNA-seq and Spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma. Front Immunol 14:1145300","journal-title":"Front Immunol"},{"key":"2046_CR248","doi-asserted-by":"crossref","unstructured":"\u0218ovrea AS et al (2022) Multiple faces of the glioblastoma microenvironment. Int J Mol Sci, 23(2):595","DOI":"10.3390\/ijms23020595"},{"issue":"1","key":"2046_CR249","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X (2020) Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol 13(1):165","journal-title":"J Hematol Oncol"},{"key":"2046_CR250","doi-asserted-by":"publisher","first-page":"1230822","DOI":"10.3389\/fphar.2023.1230822","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yu X (2023) Crosstalk between Wnt\/\u03b2-catenin signaling pathway and DNA damage response in cancer: a new direction for overcoming therapy resistance. Front Pharmacol 14:1230822","journal-title":"Front Pharmacol"},{"issue":"3","key":"2046_CR251","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10565-019-09502-7","volume":"36","author":"VS Tomar","year":"2020","unstructured":"Tomar VS, Patil V, Somasundaram K (2020) Temozolomide induces activation of Wnt\/\u03b2-catenin signaling in glioma cells via PI3K\/Akt pathway: implications in glioma therapy. Cell Biol Toxicol 36(3):273\u2013278","journal-title":"Cell Biol Toxicol"},{"issue":"6","key":"2046_CR252","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noac288","volume":"25","author":"Y Xie","year":"2023","unstructured":"Xie Y et al (2023) Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. Neuro Oncol 25(6):1073\u20131084","journal-title":"Neuro Oncol"},{"issue":"3","key":"2046_CR253","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","volume":"42","author":"KH Kim","year":"2024","unstructured":"Kim KH et al (2024) Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell 42(3):358\u2013377e8","journal-title":"Cancer Cell"},{"issue":"1","key":"2046_CR254","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C et al (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204","journal-title":"Signal Transduct Target Ther"},{"key":"2046_CR255","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","volume":"11","author":"Q Hu","year":"2023","unstructured":"Hu Q et al (2023) JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol 11:1110765","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"2046_CR256","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","volume":"31","author":"XN Zhang","year":"2021","unstructured":"Zhang XN et al (2021) Pericytes augment glioblastoma cell resistance to Temozolomide through CCL5-CCR5 paracrine signaling. Cell Res 31(10):1072\u20131087","journal-title":"Cell Res"},{"issue":"48","key":"2046_CR257","doi-asserted-by":"publisher","first-page":"e2409753","DOI":"10.1002\/advs.202409753","volume":"11","author":"L Yi","year":"2024","unstructured":"Yi L et al (2024) BRD4 degradation enhanced glioma sensitivity to Temozolomide by regulating Notch1 via Glu-Modified GSH-Responsive nanoparticles. Adv Sci (Weinh) 11(48):e2409753","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2046_CR258","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13046-020-01750-4","volume":"39","author":"W Alafate","year":"2020","unstructured":"Alafate W et al (2020) Loss of PLK2 induces acquired resistance to Temozolomide in GBM via activation of Notch signaling. J Exp Clin Cancer Res 39(1):239","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2046_CR259","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","volume":"14","author":"I Noorani","year":"2023","unstructured":"Noorani I, de la Rosa J (2023) Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat Commun 14(1):5909","journal-title":"Nat Commun"},{"issue":"5","key":"2046_CR260","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","volume":"24","author":"KH Narsinh","year":"2024","unstructured":"Narsinh KH et al (2024) Strategies to improve drug delivery across the Blood-Brain barrier for glioblastoma. Curr Neurol Neurosci Rep 24(5):123\u2013139","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2046_CR261","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jconrel.2021.07.003","volume":"336","author":"PS Yasaswi","year":"2021","unstructured":"Yasaswi PS, Shetty K, Yadav KS (2021) Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. J Control Release 336:549\u2013571","journal-title":"J Control Release"},{"key":"2046_CR262","doi-asserted-by":"crossref","unstructured":"Amarandi RM et al (2022) Liposomal-Based formulations: A path from basic research to Temozolomide delivery inside glioblastoma tissue. Pharmaceutics, 14(2):308","DOI":"10.3390\/pharmaceutics14020308"},{"key":"2046_CR263","doi-asserted-by":"publisher","first-page":"965789","DOI":"10.3389\/fphar.2022.965789","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S et al (2022) Temozolomide hexadecyl ester targeted Plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. Front Pharmacol 13:965789","journal-title":"Front Pharmacol"},{"key":"2046_CR264","doi-asserted-by":"crossref","unstructured":"Ziegler JN, Tian C (2023) Engineered extracellular vesicles: emerging therapeutic strategies for translational applications. Int J Mol Sci, 24(20):15206","DOI":"10.3390\/ijms242015206"},{"key":"2046_CR265","doi-asserted-by":"crossref","unstructured":"Tay MRJ, Seah JD, Chua KSG (2022) Long-Term outcomes of patients with primary brain tumors after acute rehabilitation: A retrospective analyses of factors. Life (Basel), 12(8):1208","DOI":"10.3390\/life12081208"},{"key":"2046_CR266","doi-asserted-by":"publisher","first-page":"339550","DOI":"10.1016\/j.aca.2022.339550","volume":"1198","author":"G Soufi","year":"2022","unstructured":"Soufi G et al (2022) Perylene diimide-POSS network for semi selective solid-phase Microextraction of lung cancer biomarkers in exhaled breath. Anal Chim Acta 1198:339550","journal-title":"Anal Chim Acta"},{"issue":"18","key":"2046_CR267","doi-asserted-by":"publisher","first-page":"e2207248","DOI":"10.1002\/smll.202207248","volume":"19","author":"X Zhong","year":"2023","unstructured":"Zhong X et al (2023) Polyhedral oligomeric Silsesquioxane-Based nanoparticles for efficient chemotherapy of glioblastoma. Small 19(18):e2207248","journal-title":"Small"},{"issue":"43","key":"2046_CR268","doi-asserted-by":"publisher","first-page":"39525","DOI":"10.1021\/acsami.9b13829","volume":"11","author":"W Fu","year":"2019","unstructured":"Fu W et al (2019) Enhanced efficacy of Temozolomide loaded by a tetrahedral framework DNA nanoparticle in the therapy for glioblastoma. ACS Appl Mater Interfaces 11(43):39525\u201339533","journal-title":"ACS Appl Mater Interfaces"},{"issue":"9","key":"2046_CR269","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-18-1250","volume":"18","author":"A Renziehausen","year":"2019","unstructured":"Renziehausen A et al (2019) Encapsulation of Temozolomide in a Calixarene nanocapsule improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer Ther 18(9):1497\u20131505","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"2046_CR270","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1080\/17435889.2024.2395234","volume":"19","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P et al (2024) Co-delivery of Temozolomide and Quercetin with folic acid-conjugated exosomes in glioblastoma treatment. Nanomed (Lond) 19(27):2271\u20132287","journal-title":"Nanomed (Lond)"},{"issue":"45","key":"2046_CR271","doi-asserted-by":"publisher","first-page":"e2104779","DOI":"10.1002\/adma.202104779","volume":"33","author":"T Jiang","year":"2021","unstructured":"Jiang T et al (2021) Cation-Free SiRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Adv Mater 33(45):e2104779","journal-title":"Adv Mater"},{"issue":"47","key":"2046_CR272","doi-asserted-by":"publisher","first-page":"55851","DOI":"10.1021\/acsami.1c16962","volume":"13","author":"K Du","year":"2021","unstructured":"Du K et al (2021) Visible light and glutathione dually responsive delivery of a Polymer-Conjugated Temozolomide intermediate for glioblastoma chemotherapy. ACS Appl Mater Interfaces 13(47):55851\u201355861","journal-title":"ACS Appl Mater Interfaces"},{"key":"2046_CR273","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.2147\/IJN.S330187","volume":"16","author":"Z Wan","year":"2021","unstructured":"Wan Z et al (2021) Accurately controlled delivery of Temozolomide by biocompatible UiO-66-NH(2) through ultrasound to enhance the antitumor efficacy and attenuate the toxicity for treatment of malignant glioma. Int J Nanomed 16:6905\u20136922","journal-title":"Int J Nanomed"},{"issue":"12","key":"2046_CR274","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1021\/acsabm.3c00644","volume":"6","author":"U Hasan","year":"2023","unstructured":"Hasan U, Rajakumara E, Giri J (2023) Reversal of multidrug resistance by the synergistic effect of reversan and hyperthermia to potentiate the chemotherapeutic response of doxorubicin in glioblastoma and glioblastoma stem cells. ACS Appl Bio Mater 6(12):5399\u20135413","journal-title":"ACS Appl Bio Mater"},{"key":"2046_CR275","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jconrel.2023.03.040","volume":"357","author":"TI Janjua","year":"2023","unstructured":"Janjua TI et al (2023) Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. J Control Release 357:161\u2013174","journal-title":"J Control Release"},{"issue":"3","key":"2046_CR276","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/neuonc\/noaa255","volume":"23","author":"K Yi","year":"2021","unstructured":"Yi K et al (2021) PTRF\/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2. Neuro Oncol 23(3):387\u2013399","journal-title":"Neuro Oncol"},{"issue":"7","key":"2046_CR277","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.7150\/thno.92703","volume":"14","author":"J Zhao","year":"2024","unstructured":"Zhao J et al (2024) CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis\/tmz resistance in the mesenchymal subtype of glioblastoma. Theranostics 14(7):2835\u20132855","journal-title":"Theranostics"},{"key":"2046_CR278","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jconrel.2023.10.024","volume":"364","author":"BJ Umlauf","year":"2023","unstructured":"Umlauf BJ et al (2023) A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal\/cerebral spinal fluid clearance rate. J Control Release 364:195\u2013205","journal-title":"J Control Release"},{"issue":"4","key":"2046_CR279","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R et al (2021) Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol 19(4):513\u2013537","journal-title":"Curr Neuropharmacol"},{"key":"2046_CR280","doi-asserted-by":"publisher","first-page":"107922","DOI":"10.1016\/j.pharmthera.2021.107922","volume":"228","author":"F Lang","year":"2021","unstructured":"Lang F et al (2021) Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther 228:107922","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2046_CR281","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/neuonc\/noac242","volume":"25","author":"J Zhao","year":"2023","unstructured":"Zhao J et al (2023) A novel compound EPIC-0412 reverses Temozolomide resistance via inhibiting DNA repair\/mgmt in glioblastoma. Neuro Oncol 25(5):857\u2013870","journal-title":"Neuro Oncol"},{"issue":"11","key":"2046_CR282","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/neuonc\/noad102","volume":"25","author":"L Xin","year":"2023","unstructured":"Xin L et al (2023) EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of Temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro Oncol 25(11):1976\u20131988","journal-title":"Neuro Oncol"},{"key":"2046_CR283","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.drup.2024.101122","volume":"76","author":"Y Lan","year":"2024","unstructured":"Lan Y et al (2024) Framework nucleic acid-based nanoparticles enhance Temozolomide sensitivity in glioblastoma. Drug Resist Updat 76:101122","journal-title":"Drug Resist Updat"},{"key":"2046_CR284","doi-asserted-by":"publisher","first-page":"121608","DOI":"10.1016\/j.biomaterials.2022.121608","volume":"287","author":"M Ismail","year":"2022","unstructured":"Ismail M et al (2022) Targeted liposomes for combined delivery of Artesunate and Temozolomide to resistant glioblastoma. Biomaterials 287:121608","journal-title":"Biomaterials"},{"key":"2046_CR285","doi-asserted-by":"publisher","first-page":"154933","DOI":"10.1016\/j.phymed.2023.154933","volume":"118","author":"W Wang","year":"2023","unstructured":"Wang W et al (2023) Quercetin induces MGMT(+) glioblastoma cells apoptosis via dual Inhibition of Wnt3a\/\u03b2-Catenin and Akt\/NF-\u03baB signaling pathways. Phytomedicine 118:154933","journal-title":"Phytomedicine"},{"key":"2046_CR286","doi-asserted-by":"publisher","first-page":"154016","DOI":"10.1016\/j.phymed.2022.154016","volume":"99","author":"Q Tang","year":"2022","unstructured":"Tang Q et al (2022) Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K\/Akt\/mTOR\/NF-\u03baB-mediated signaling pathway. Phytomedicine 99:154016","journal-title":"Phytomedicine"},{"issue":"12","key":"2046_CR287","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41419-022-05497-y","volume":"13","author":"A Tancredi","year":"2022","unstructured":"Tancredi A et al (2022) BET protein Inhibition sensitizes glioblastoma cells to Temozolomide treatment by attenuating MGMT expression. Cell Death Dis 13(12):1037","journal-title":"Cell Death Dis"},{"issue":"5","key":"2046_CR288","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1021\/acsnano.1c09794","volume":"16","author":"D Liu","year":"2022","unstructured":"Liu D et al (2022) Nano-Codelivery of Temozolomide and siPD-L1 to reprogram the Drug-Resistant and immunosuppressive microenvironment in orthotopic glioblastoma. ACS Nano 16(5):7409\u20137427","journal-title":"ACS Nano"},{"key":"2046_CR289","doi-asserted-by":"crossref","unstructured":"Li Z et al (2024) Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme. J Med Chem, 67(17): pp. 15691\u201315710","DOI":"10.1021\/acs.jmedchem.4c01304"},{"issue":"5","key":"2046_CR290","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cns.13591","volume":"27","author":"YH Hu","year":"2021","unstructured":"Hu YH et al (2021) Regulation of Temozolomide resistance in glioma cells via the RIP2\/NF-\u03baB\/MGMT pathway. CNS Neurosci Ther 27(5):552\u2013563","journal-title":"CNS Neurosci Ther"},{"key":"2046_CR291","doi-asserted-by":"crossref","unstructured":"How JA et al (2021) Modification of homologous recombination deficiency score threshold and association with Long-Term survival in epithelial ovarian Cancer. Cancers (Basel), 13(5):946","DOI":"10.3390\/cancers13050946"},{"key":"2046_CR292","doi-asserted-by":"crossref","unstructured":"Sim HW, Galanis E, Khasraw M (2022) PARP inhibitors in glioma: A review of therapeutic opportunities. Cancers (Basel), 14(4):1003","DOI":"10.3390\/cancers14041003"},{"issue":"3","key":"2046_CR293","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-020-03561-1","volume":"148","author":"AL Yuan","year":"2020","unstructured":"Yuan AL et al (2020) PARP Inhibition suppresses the emergence of Temozolomide resistance in a model system. J Neurooncol 148(3):463\u2013472","journal-title":"J Neurooncol"},{"issue":"3","key":"2046_CR294","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-023-04514-0","volume":"165","author":"L Kleinberg","year":"2023","unstructured":"Kleinberg L et al (2023) A multi-site phase I trial of veliparib with standard radiation and Temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM). J Neurooncol 165(3):499\u2013507","journal-title":"J Neurooncol"},{"issue":"7","key":"2046_CR295","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-19-2000","volume":"26","author":"F Higuchi","year":"2020","unstructured":"Higuchi F et al (2020) Restoration of Temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res 26(7):1690\u20131699","journal-title":"Clin Cancer Res"},{"key":"2046_CR296","doi-asserted-by":"crossref","unstructured":"McCord M et al (2024) The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro Oncol 27(3):644\u2013651","DOI":"10.1093\/neuonc\/noae257"},{"issue":"7","key":"2046_CR297","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","volume":"30","author":"AD Staniszewska","year":"2024","unstructured":"Staniszewska AD et al (2024) Preclinical characterization of AZD9574, a Blood-Brain barrier penetrant inhibitor of PARP1. Clin Cancer Res 30(7):1338\u20131351","journal-title":"Clin Cancer Res"},{"key":"2046_CR298","doi-asserted-by":"crossref","unstructured":"Zampieri LX et al (2021) Olaparib is a mitochondrial complex I inhibitor that kills Temozolomide-Resistant human glioblastoma cells. Int J Mol Sci, 22(21):11938","DOI":"10.3390\/ijms222111938"},{"issue":"1","key":"2046_CR299","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13014-022-02052-z","volume":"17","author":"LE Schn\u00f6ller","year":"2022","unstructured":"Schn\u00f6ller LE et al (2022) Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiat Oncol 17(1):79","journal-title":"Radiat Oncol"},{"issue":"7","key":"2046_CR300","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.7150\/thno.41219","volume":"10","author":"B Han","year":"2020","unstructured":"Han B et al (2020) ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics 10(7):3351\u20133365","journal-title":"Theranostics"},{"key":"2046_CR301","doi-asserted-by":"crossref","unstructured":"Barszczewska-Pietraszek G et al (2024) Pol\u03b8 inhibitor (ART558) demonstrates a synthetic lethal effect with PARP and RAD52 inhibitors in glioblastoma cells. Int J Mol Sci, 25(17):9134","DOI":"10.3390\/ijms25179134"},{"issue":"3","key":"2046_CR302","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/ibd\/izaa161","volume":"27","author":"L Sahakian","year":"2021","unstructured":"Sahakian L et al (2021) Inhibition of APE1\/Ref-1 redox signaling alleviates intestinal dysfunction and damage to myenteric neurons in a mouse model of spontaneous chronic colitis. Inflamm Bowel Dis 27(3):388\u2013406","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2046_CR303","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2023.04.035","volume":"165","author":"S Kumar","year":"2023","unstructured":"Kumar S et al (2023) Elevated APE1 dysregulates homologous recombination and cell cycle driving genomic evolution, tumorigenesis, and chemoresistance in esophageal adenocarcinoma. Gastroenterology 165(2):357\u2013373","journal-title":"Gastroenterology"},{"key":"2046_CR304","doi-asserted-by":"crossref","unstructured":"Zoi V et al (2023) Therapeutic potential of linearol in combination with radiotherapy for the treatment of glioblastoma in vitro. Int J Mol Sci, 24(4):3760","DOI":"10.3390\/ijms24043760"},{"issue":"15","key":"2046_CR305","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1158\/1078-0432.CCR-23-4098","volume":"30","author":"MS Ahluwalia","year":"2024","unstructured":"Ahluwalia MS et al (2024) Evaluating the base excision repair inhibitor TRC102 and Temozolomide for patients with recurrent glioblastoma in the phase 2 adult brain tumor consortium trial BERT. Clin Cancer Res 30(15):3167\u20133178","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2046_CR306","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/neuonc\/noad159","volume":"26","author":"B Hong","year":"2024","unstructured":"Hong B et al (2024) EPIC-1042 as a potent PTRF\/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress Temozolomide efflux for glioblastoma. Neuro Oncol 26(1):100\u2013114","journal-title":"Neuro Oncol"},{"key":"2046_CR307","doi-asserted-by":"crossref","unstructured":"M, A., et al., Epigenetic basis for PARP mutagenesis in glioblastoma: A review. Eur J Pharmacol, (2023) 938: p. 175424","DOI":"10.1016\/j.ejphar.2022.175424"},{"key":"2046_CR308","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.dnarep.2024.103700","volume":"140","author":"KM Saville","year":"2024","unstructured":"Saville KM et al (2024) Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG Inhibition induced cytotoxicity. DNA Repair (Amst) 140:103700","journal-title":"DNA Repair (Amst)"},{"key":"2046_CR309","doi-asserted-by":"crossref","unstructured":"Fujii S, Fuchs RP (2024) Accidental encounter of repair intermediates in alkylated DNA May lead to Double-Strand breaks in resting cells. Int J Mol Sci, 25(15):8192","DOI":"10.3390\/ijms25158192"},{"key":"2046_CR310","doi-asserted-by":"crossref","unstructured":"Shin MH et al (2023) Recent advances in CAR-Based solid tumor immunotherapy. Cells, 12(12):1606","DOI":"10.3390\/cells12121606"},{"issue":"8","key":"2046_CR311","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"AD Posey Jr","year":"2024","unstructured":"Posey AD Jr., Young RM, June CH (2024) Future perspectives on engineered T cells for cancer. Trends Cancer 10(8):687\u2013695","journal-title":"Trends Cancer"},{"key":"2046_CR312","doi-asserted-by":"crossref","unstructured":"Lechpammer M et al (2022) Advances in immunotherapy for the treatment of adult glioblastoma: overcoming chemical and physical barriers. Cancers (Basel), 14(7):1627","DOI":"10.3390\/cancers14071627"},{"issue":"9","key":"2046_CR313","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","volume":"20","author":"CM Jackson","year":"2019","unstructured":"Jackson CM, Choi J, Lim M (2019) Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 20(9):1100\u20131109","journal-title":"Nat Immunol"},{"key":"2046_CR314","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud M et al (2023) Novel targets for immune-checkpoint Inhibition in cancer. Cancer Treat Rev 120:102614","journal-title":"Cancer Treat Rev"},{"key":"2046_CR315","doi-asserted-by":"publisher","first-page":"662064","DOI":"10.3389\/fnins.2021.662064","volume":"15","author":"L Maggs","year":"2021","unstructured":"Maggs L et al (2021) CAR T Cell-Based immunotherapy for the treatment of glioblastoma. Front Neurosci 15:662064","journal-title":"Front Neurosci"},{"issue":"7738","key":"2046_CR316","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234\u2013239","journal-title":"Nature"},{"key":"2046_CR317","doi-asserted-by":"publisher","first-page":"679425","DOI":"10.3389\/fimmu.2021.679425","volume":"12","author":"A Ghouzlani","year":"2021","unstructured":"Ghouzlani A et al (2021) Immune checkpoint inhibitors in human glioma microenvironment. Front Immunol 12:679425","journal-title":"Front Immunol"},{"issue":"3","key":"2046_CR318","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477\u2013486","journal-title":"Nat Med"},{"key":"2046_CR319","doi-asserted-by":"publisher","first-page":"100376","DOI":"10.1016\/j.clinsp.2024.100376","volume":"79","author":"RZ Kuang","year":"2024","unstructured":"Kuang RZ et al (2024) Effects of apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma. Clin (Sao Paulo) 79:100376","journal-title":"Clin (Sao Paulo)"},{"key":"2046_CR320","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","volume":"476","author":"S Xu","year":"2020","unstructured":"Xu S et al (2020) Immunotherapy for glioma: current management and future application. Cancer Lett 476:1\u201312","journal-title":"Cancer Lett"},{"issue":"9","key":"2046_CR321","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A et al (2023) Ipilimumab with or without nivolumab in PD-1 or PD-L1 Blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278\u20132285","journal-title":"Nat Med"},{"issue":"5 Suppl 1","key":"2046_CR322","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1590\/0004-282x-anp-2022-s129","volume":"80","author":"A Omuro","year":"2022","unstructured":"Omuro A (2022) Immune-checkpoint inhibitors for glioblastoma: what have we learned? Arq Neuropsiquiatr 80(5 Suppl 1):266\u2013269","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"2046_CR323","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003\u20131010","journal-title":"JAMA Oncol"},{"key":"2046_CR324","doi-asserted-by":"crossref","unstructured":"Rodriguez SMB et al (2024) Glioblastoma and immune checkpoint inhibitors: A glance at available treatment options and future directions. Int J Mol Sci, 25(19):10765","DOI":"10.3390\/ijms251910765"},{"issue":"9","key":"2046_CR325","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/neuonc\/noae058","volume":"26","author":"AE Sloan","year":"2024","unstructured":"Sloan AE et al (2024) NRG-BN002: phase I study of Ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro Oncol 26(9):1628\u20131637","journal-title":"Neuro Oncol"},{"issue":"4","key":"2046_CR326","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1021\/acsami.4c16960","volume":"17","author":"X Song","year":"2025","unstructured":"Song X et al (2025) Hybrid membrane biomimetic photothermal nanorobots for enhanced Chemodynamic-Chemotherapy-Immunotherapy. ACS Appl Mater Interfaces 17(4):5784\u20135798","journal-title":"ACS Appl Mater Interfaces"},{"key":"2046_CR327","doi-asserted-by":"publisher","first-page":"1438044","DOI":"10.3389\/fimmu.2024.1438044","volume":"15","author":"L Sloan","year":"2024","unstructured":"Sloan L et al (2024) Radiation immunodynamics in patients with glioblastoma receiving chemoradiation. Front Immunol 15:1438044","journal-title":"Front Immunol"},{"issue":"10","key":"2046_CR328","doi-asserted-by":"publisher","first-page":"11657","DOI":"10.1021\/acsami.1c00347","volume":"13","author":"L Meng","year":"2021","unstructured":"Meng L et al (2021) Targeted regulation of Blood-Brain barrier for enhanced therapeutic efficiency of Hypoxia-Modifier nanoparticles and immune checkpoint Blockade antibodies for glioblastoma. ACS Appl Mater Interfaces 13(10):11657\u201311671","journal-title":"ACS Appl Mater Interfaces"},{"key":"2046_CR329","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.actbio.2024.09.054","volume":"189","author":"Q Gao","year":"2024","unstructured":"Gao Q et al (2024) Versatile self-assembled near-infrared SERS nanoprobes for multidrug-resistant bacterial infection-specific surveillance and therapy. Acta Biomater 189:559\u2013573","journal-title":"Acta Biomater"},{"key":"2046_CR330","doi-asserted-by":"publisher","first-page":"875648","DOI":"10.3389\/fimmu.2022.875648","volume":"13","author":"M Chen","year":"2022","unstructured":"Chen M et al (2022) DNA damage response evaluation provides novel insights for personalized immunotherapy in glioma. Front Immunol 13:875648","journal-title":"Front Immunol"},{"key":"2046_CR331","doi-asserted-by":"publisher","first-page":"910490","DOI":"10.3389\/fimmu.2022.910490","volume":"13","author":"Y Cai","year":"2022","unstructured":"Cai Y et al (2022) Lighting a fire: Gasdermin-Mediated pyroptosis remodels the glioma microenvironment and promotes immune checkpoint Blockade response. Front Immunol 13:910490","journal-title":"Front Immunol"},{"key":"2046_CR332","doi-asserted-by":"publisher","first-page":"1255611","DOI":"10.3389\/fimmu.2023.1255611","volume":"14","author":"F Yasinjan","year":"2023","unstructured":"Yasinjan F et al (2023) Immunotherapy: a promising approach for glioma treatment. Front Immunol 14:1255611","journal-title":"Front Immunol"},{"issue":"1","key":"2046_CR333","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12951-024-02882-x","volume":"22","author":"I Karimi-Sani","year":"2024","unstructured":"Karimi-Sani I et al (2024) Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials. J Nanobiotechnol 22(1):601","journal-title":"J Nanobiotechnol"},{"key":"2046_CR334","doi-asserted-by":"crossref","unstructured":"Burkholz SR et al (2023) Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: A potential neoadjuvant T cell immunotherapy for triple negative breast cancer: A preliminary study. Vaccines (Basel), 11(3)","DOI":"10.3390\/vaccines11030644"},{"key":"2046_CR335","doi-asserted-by":"publisher","first-page":"952237","DOI":"10.3389\/fbioe.2022.952237","volume":"10","author":"H Miao","year":"2022","unstructured":"Miao H et al (2022) A nanobody-based molecular toolkit for ubiquitin-proteasome system explores the main role of survivin subcellular localization. Front Bioeng Biotechnol 10:952237","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"2046_CR336","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41419-021-03568-0","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X et al (2021) Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis 12(4):299","journal-title":"Cell Death Dis"},{"issue":"7","key":"2046_CR337","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS et al (2023) Phase IIa study of survaxm plus adjuvant Temozolomide for newly diagnosed glioblastoma. J Clin Oncol 41(7):1453\u20131465","journal-title":"J Clin Oncol"},{"issue":"1","key":"2046_CR338","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM et al (2023) Association of autologous tumor Lysate-Loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial. JAMA Oncol 9(1):112\u2013121","journal-title":"JAMA Oncol"},{"key":"2046_CR339","doi-asserted-by":"publisher","first-page":"1404861","DOI":"10.3389\/fimmu.2024.1404861","volume":"15","author":"L Ridolfi","year":"2024","unstructured":"Ridolfi L et al (2024) First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax). Front Immunol 15:1404861","journal-title":"Front Immunol"},{"issue":"2","key":"2046_CR340","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","volume":"21","author":"E Faghfuri","year":"2021","unstructured":"Faghfuri E et al (2021) Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther 21(2):201\u2013218","journal-title":"Expert Opin Biol Ther"},{"key":"2046_CR341","doi-asserted-by":"crossref","unstructured":"Eralp Y (2022) Application of mRNA technology in Cancer therapeutics. Vaccines (Basel), 10(8)","DOI":"10.3390\/vaccines10081262"},{"issue":"11","key":"2046_CR342","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan F et al (2022) Therapeutic targeting of regulatory T cells in cancer. Trends Cancer 8(11):944\u2013961","journal-title":"Trends Cancer"},{"key":"2046_CR343","doi-asserted-by":"publisher","first-page":"680021","DOI":"10.3389\/fphar.2021.680021","volume":"12","author":"MS Alghamri","year":"2021","unstructured":"Alghamri MS et al (2021) Targeting neuroinflammation in brain cancer: Uncovering mechanisms, Pharmacological targets, and neuropharmaceutical developments. Front Pharmacol 12:680021","journal-title":"Front Pharmacol"},{"issue":"16","key":"2046_CR344","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1158\/1078-0432.CCR-20-0341","volume":"26","author":"L Scheetz","year":"2020","unstructured":"Scheetz L et al (2020) Synthetic High-density lipoprotein nanodiscs for personalized immunotherapy against gliomas. Clin Cancer Res 26(16):4369\u20134380","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2046_CR345","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3171\/2022.12.JNS221221","volume":"139","author":"Y Muragaki","year":"2023","unstructured":"Muragaki Y et al (2023) A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas. J Neurosurg 139(2):344\u2013354","journal-title":"J Neurosurg"},{"issue":"4","key":"2046_CR346","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","volume":"28","author":"JL Hu","year":"2022","unstructured":"Hu JL et al (2022) A phase I study of autologous dendritic cell vaccine pulsed with allogeneic Stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin Cancer Res 28(4):689\u2013696","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2046_CR347","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-020-6589-x","volume":"20","author":"R Tamura","year":"2020","unstructured":"Tamura R et al (2020) Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. BMC Cancer 20(1):196","journal-title":"BMC Cancer"},{"issue":"10","key":"2046_CR348","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00262-023-03482-8","volume":"72","author":"J Takei","year":"2023","unstructured":"Takei J et al (2023) Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 72(10):3175\u20133189","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2046_CR349","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13046-022-02552-6","volume":"41","author":"DA Bota","year":"2022","unstructured":"Bota DA et al (2022) Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res 41(1):344","journal-title":"J Exp Clin Cancer Res"},{"key":"2046_CR350","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fonc.2020.00089","volume":"10","author":"V Dutoit","year":"2020","unstructured":"Dutoit V et al (2020) Impact of radiochemotherapy on immune cell subtypes in High-Grade glioma patients. Front Oncol 10:89","journal-title":"Front Oncol"},{"key":"2046_CR351","doi-asserted-by":"crossref","unstructured":"Hamad A et al (2023) Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses, 15(2):547","DOI":"10.3390\/v15020547"},{"key":"2046_CR352","doi-asserted-by":"publisher","first-page":"603911","DOI":"10.3389\/fimmu.2020.603911","volume":"11","author":"B Huang","year":"2020","unstructured":"Huang B et al (2020) Current immunotherapies for glioblastoma multiforme. Front Immunol 11:603911","journal-title":"Front Immunol"},{"issue":"8","key":"2046_CR353","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T et al (2022) Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630\u20131639","journal-title":"Nat Med"},{"key":"2046_CR354","doi-asserted-by":"crossref","unstructured":"Sostoa J, Dutoit V, Migliorini D (2020) Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci, 21(20):7449","DOI":"10.3390\/ijms21207449"},{"key":"2046_CR355","doi-asserted-by":"crossref","unstructured":"Baugh R et al (2024) Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. J Immunother Cancer, 12(5):e008460","DOI":"10.1136\/jitc-2023-008460"},{"issue":"8","key":"2046_CR356","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","volume":"22","author":"J Fares","year":"2021","unstructured":"Fares J et al (2021) Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol 22(8):1103\u20131114","journal-title":"Lancet Oncol"},{"key":"2046_CR357","doi-asserted-by":"crossref","unstructured":"Kadhim ZA et al (2022) Oncolytic Newcastle disease virus Co-Delivered with modified PLGA nanoparticles encapsulating Temozolomide against glioblastoma cells: developing an effective treatment strategy. Molecules, 27(18):5757","DOI":"10.3390\/molecules27185757"},{"key":"2046_CR358","doi-asserted-by":"crossref","unstructured":"Saha D, Rabkin SD, Martuza RL (2020) Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer, 8(1):e000345","DOI":"10.1136\/jitc-2019-000345"},{"issue":"11","key":"2046_CR359","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41419-023-06156-6","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y et al (2023) RPL22L1, a novel candidate oncogene promotes Temozolomide resistance by activating STAT3 in glioblastoma. Cell Death Dis 14(11):757","journal-title":"Cell Death Dis"},{"issue":"1","key":"2046_CR360","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1038\/s41467-019-11614-x","volume":"10","author":"MSY Tan","year":"2019","unstructured":"Tan MSY et al (2019) A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nat Commun 10(1):3601","journal-title":"Nat Commun"},{"issue":"1","key":"2046_CR361","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13046-024-03254-x","volume":"44","author":"W Hu","year":"2025","unstructured":"Hu W et al (2025) CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD(+)\/NADH ratio. J Exp Clin Cancer Res 44(1):3","journal-title":"J Exp Clin Cancer Res"},{"key":"2046_CR362","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jconrel.2022.03.036","volume":"345","author":"FU Rehman","year":"2022","unstructured":"Rehman FU et al (2022) Heme Oxygenase-1 targeting exosomes for Temozolomide resistant glioblastoma synergistic therapy. J Control Release 345:696\u2013708","journal-title":"J Control Release"},{"key":"2046_CR363","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2024.10.004","volume":"376","author":"S Li","year":"2024","unstructured":"Li S et al (2024) Brain targeted biomimetic SiRNA nanoparticles for drug resistance glioblastoma treatment. J Control Release 376:67\u201378","journal-title":"J Control Release"},{"issue":"1","key":"2046_CR364","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J et al (2020) The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol 13(1):113","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2046_CR365","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41401-020-0418-2","volume":"42","author":"C Chen","year":"2021","unstructured":"Chen C et al (2021) Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacol Sin 42(1):108\u2013114","journal-title":"Acta Pharmacol Sin"},{"issue":"19","key":"2046_CR366","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41388-022-02294-x","volume":"41","author":"R Lane","year":"2022","unstructured":"Lane R et al (2022) PDGF-R Inhibition induces glioblastoma cell differentiation via DUSP1\/p38(MAPK) signalling. Oncogene 41(19):2749\u20132763","journal-title":"Oncogene"},{"issue":"5","key":"2046_CR367","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41419-024-06735-1","volume":"15","author":"W Alafate","year":"2024","unstructured":"Alafate W et al (2024) Targeting ARNT attenuates chemoresistance through destabilizing p38\u03b1-MAPK signaling in glioblastoma. Cell Death Dis 15(5):366","journal-title":"Cell Death Dis"},{"issue":"5","key":"2046_CR368","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1002\/jcp.27409","volume":"234","author":"HC Yang","year":"2019","unstructured":"Yang HC et al (2019) Resveratrol restores sensitivity of glioma cells to Temozolamide through inhibiting the activation of Wnt signaling pathway. J Cell Physiol 234(5):6783\u20136800","journal-title":"J Cell Physiol"},{"key":"2046_CR369","doi-asserted-by":"publisher","first-page":"105348","DOI":"10.1016\/j.neuint.2022.105348","volume":"157","author":"YQ Fei","year":"2022","unstructured":"Fei YQ et al (2022) Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to Temozolomide through Wnt\/\u03b2-catenin signaling pathway. Neurochem Int 157:105348","journal-title":"Neurochem Int"},{"key":"2046_CR370","doi-asserted-by":"crossref","unstructured":"Pridham KJ et al (2024) Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta. iScience, 27(6): p. 109921","DOI":"10.1016\/j.isci.2024.109921"},{"issue":"7","key":"2046_CR371","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/neuonc\/noae028","volume":"26","author":"HS Cheng","year":"2024","unstructured":"Cheng HS et al (2024) Dual p38MAPK and MEK Inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to Temozolomide. Neuro Oncol 26(7):1247\u20131261","journal-title":"Neuro Oncol"},{"issue":"1","key":"2046_CR372","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/neuonc\/noab197","volume":"24","author":"BGC Lopez","year":"2022","unstructured":"Lopez BGC et al (2022) Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol 24(1):64\u201377","journal-title":"Neuro Oncol"},{"key":"2046_CR373","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/DDDT.S252401","volume":"14","author":"CY Wang","year":"2020","unstructured":"Wang CY et al (2020) Cordycepin inhibits human gestational choriocarcinoma cell growth by disrupting centrosome homeostasis. Drug Des Devel Ther 14:2987\u20133000","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"2046_CR374","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.canlet.2015.02.012","volume":"360","author":"SW Lee","year":"2015","unstructured":"Lee SW et al (2015) The synergistic effect of combination Temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360(2):195\u2013204","journal-title":"Cancer Lett"},{"issue":"6","key":"2046_CR375","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/15548627.2019.1569947","volume":"15","author":"T Huang","year":"2019","unstructured":"Huang T et al (2019) MIR93 (microRNA\u2013\u200993) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy. Autophagy 15(6):1100\u20131111","journal-title":"Autophagy"},{"key":"2046_CR376","doi-asserted-by":"crossref","unstructured":"Zhao K et al (2021) Inhibition of carbonic anhydrase 2 overcomes Temozolomide resistance in glioblastoma cells. Int J Mol Sci, 23(1):157","DOI":"10.3390\/ijms23010157"},{"issue":"12","key":"2046_CR377","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1080\/15548627.2023.2242696","volume":"19","author":"M Ou","year":"2023","unstructured":"Ou M et al (2023) Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a Perillyl alcohol-rolipram conjugate. Autophagy 19(12):3169\u20133188","journal-title":"Autophagy"},{"issue":"1","key":"2046_CR378","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12935-023-03090-7","volume":"23","author":"P Tabnak","year":"2023","unstructured":"Tabnak P et al (2023) Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics. Cancer Cell Int 23(1):238","journal-title":"Cancer Cell Int"},{"key":"2046_CR379","doi-asserted-by":"publisher","first-page":"116113","DOI":"10.1016\/j.bcp.2024.116113","volume":"223","author":"HT Yin","year":"2024","unstructured":"Yin HT et al (2024) Daurisoline suppress glioma progression by inhibiting autophagy through PI3K\/AKT\/mTOR pathway and increases TMZ sensitivity. Biochem Pharmacol 223:116113","journal-title":"Biochem Pharmacol"},{"key":"2046_CR380","doi-asserted-by":"publisher","first-page":"117657","DOI":"10.1016\/j.bmc.2024.117657","volume":"102","author":"D Li","year":"2024","unstructured":"Li D et al (2024) AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy. Bioorg Med Chem 102:117657","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2046_CR381","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12935-023-03191-3","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway. Cancer Cell Int 24(1):69","journal-title":"Cancer Cell Int"},{"key":"2046_CR382","doi-asserted-by":"publisher","first-page":"e16691","DOI":"10.7717\/peerj.16691","volume":"12","author":"L Lin","year":"2024","unstructured":"Lin L et al (2024) Borneol promotes autophagic degradation of HIF-1\u03b1 and enhances chemotherapy sensitivity in malignant glioma. PeerJ 12:e16691","journal-title":"PeerJ"},{"key":"2046_CR383","doi-asserted-by":"publisher","first-page":"749987","DOI":"10.3389\/fonc.2021.749987","volume":"11","author":"Q Li","year":"2021","unstructured":"Li Q et al (2021) Role of Borneol induced autophagy in enhancing radiosensitivity of malignant glioma. Front Oncol 11:749987","journal-title":"Front Oncol"},{"issue":"11","key":"2046_CR384","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1080\/15548627.2021.1885203","volume":"17","author":"T Huang","year":"2021","unstructured":"Huang T et al (2021) Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. Autophagy 17(11):3592\u20133606","journal-title":"Autophagy"},{"key":"2046_CR385","doi-asserted-by":"publisher","first-page":"102451","DOI":"10.1016\/j.redox.2022.102451","volume":"56","author":"K Li","year":"2022","unstructured":"Li K et al (2022) TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells. Redox Biol 56:102451","journal-title":"Redox Biol"},{"issue":"16","key":"2046_CR386","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-22-3971","volume":"29","author":"L Shi","year":"2023","unstructured":"Shi L et al (2023) The DRD2 antagonist haloperidol mediates Autophagy-Induced ferroptosis to increase Temozolomide sensitivity by promoting Endoplasmic reticulum stress in glioblastoma. Clin Cancer Res 29(16):3172\u20133188","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2046_CR387","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-022-02291-8","volume":"41","author":"Z Li","year":"2022","unstructured":"Li Z et al (2022) Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to Temozolomide through macrophage M1-like polarization. J Exp Clin Cancer Res 41(1):74","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2046_CR388","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11010-022-04423-2","volume":"477","author":"ML Corr\u00eaa-Ferreira","year":"2022","unstructured":"Corr\u00eaa-Ferreira ML et al (2022) The mesoionic compound MI-D changes energy metabolism and induces apoptosis in T98G glioma cells. Mol Cell Biochem 477(8):2033\u20132045","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"2046_CR389","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s42003-022-03986-6","volume":"5","author":"JY Zhu","year":"2022","unstructured":"Zhu JY et al (2022) SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA\/MAX complex-mediated increased Glycolysis. Commun Biol 5(1):1039","journal-title":"Commun Biol"},{"key":"2046_CR390","doi-asserted-by":"crossref","unstructured":"Pucci G et al (2024) Glut-3 gene knockdown as a potential strategy to overcome glioblastoma radioresistance. Int J Mol Sci, 25(4):2079","DOI":"10.3390\/ijms25042079"},{"key":"2046_CR391","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2022.12.001","volume":"88","author":"C Heuser","year":"2023","unstructured":"Heuser C et al (2023) Targeting lactate metabolism for cancer immunotherapy - a matter of precision. Semin Cancer Biol 88:32\u201345","journal-title":"Semin Cancer Biol"},{"key":"2046_CR392","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semcancer.2022.11.007","volume":"87","author":"D Sharma","year":"2022","unstructured":"Sharma D, Singh M, Rani R (2022) Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. Semin Cancer Biol 87:184\u2013195","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"2046_CR393","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41419-022-05175-z","volume":"13","author":"K Luo","year":"2022","unstructured":"Luo K et al (2022) CircKIF4A promotes glioma growth and Temozolomide resistance by accelerating Glycolysis. Cell Death Dis 13(8):740","journal-title":"Cell Death Dis"},{"key":"2046_CR394","doi-asserted-by":"crossref","unstructured":"Fhu CW, Ali A (2020) Fatty acid synthase: an emerging target in Cancer. Molecules, 25(17):3935","DOI":"10.3390\/molecules25173935"},{"key":"2046_CR395","doi-asserted-by":"publisher","first-page":"155794","DOI":"10.1016\/j.metabol.2024.155794","volume":"153","author":"Z Hao","year":"2024","unstructured":"Hao Z et al (2024) Identification of MGMT promoter methylation as a specific lipid metabolism biomarker, reveals the feasibility of Atorvastatin application in glioblastoma. Metabolism 153:155794","journal-title":"Metabolism"},{"key":"2046_CR396","doi-asserted-by":"crossref","unstructured":"Liu X et al (2024) IMPDH Inhibition decreases TERT expression and synergizes the cytotoxic effect of chemotherapeutic agents in glioblastoma cells. Int J Mol Sci, 25(11):5992","DOI":"10.3390\/ijms25115992"},{"issue":"8042","key":"2046_CR397","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-024-08224-z","volume":"636","author":"YJ Chen","year":"2024","unstructured":"Chen YJ et al (2024) Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. Nature 636(8042):466\u2013473","journal-title":"Nature"},{"issue":"4","key":"2046_CR398","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/brain\/awab020","volume":"144","author":"JM Shireman","year":"2021","unstructured":"Shireman JM et al (2021) De Novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain 144(4):1230\u20131246","journal-title":"Brain"},{"issue":"5","key":"2046_CR399","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten M et al (2019) Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 18(5):379\u2013401","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2046_CR400","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0103-4","volume":"5","author":"L Du","year":"2020","unstructured":"Du L et al (2020) Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct Target Ther 5(1):10","journal-title":"Signal Transduct Target Ther"},{"key":"2046_CR401","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ejmech.2018.11.010","volume":"162","author":"M Winters","year":"2019","unstructured":"Winters M et al (2019) Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and Tryptophan dioxygenase. Eur J Med Chem 162:455\u2013464","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2046_CR402","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1186\/s12885-024-12631-w","volume":"24","author":"MJ Bickerdike","year":"2024","unstructured":"Bickerdike MJ et al (2024) AT-0174, a novel dual IDO1\/TDO2 enzyme inhibitor, synergises with Temozolomide to improve survival in an orthotopic mouse model of glioblastoma. BMC Cancer 24(1):889","journal-title":"BMC Cancer"},{"issue":"7","key":"2046_CR403","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41419-024-06938-6","volume":"15","author":"Z Lu","year":"2024","unstructured":"Lu Z et al (2024) CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and Temozolomide sensitivity. Cell Death Dis 15(7):538","journal-title":"Cell Death Dis"},{"issue":"5","key":"2046_CR404","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","volume":"104","author":"MT Ballo","year":"2019","unstructured":"Ballo MT et al (2019) Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A Large-Scale numerical Simulation-Based analysis of data from the phase 3 EF-14 randomized trial. Int J Radiat Oncol Biol Phys 104(5):1106\u20131113","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2046_CR405","doi-asserted-by":"publisher","first-page":"111810","DOI":"10.1016\/j.biopha.2021.111810","volume":"141","author":"S Liu","year":"2021","unstructured":"Liu S et al (2021) Progress and prospect in tumor treating fields treatment of glioblastoma. Biomed Pharmacother 141:111810","journal-title":"Biomed Pharmacother"},{"issue":"20","key":"2046_CR406","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","volume":"82","author":"JC Moser","year":"2022","unstructured":"Moser JC et al (2022) The mechanisms of action of tumor treating fields. Cancer Res 82(20):3650\u20133658","journal-title":"Cancer Res"},{"issue":"2","key":"2046_CR407","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","volume":"141","author":"SA Toms","year":"2019","unstructured":"Toms SA et al (2019) Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol 141(2):467\u2013473","journal-title":"J Neurooncol"},{"key":"2046_CR408","doi-asserted-by":"publisher","first-page":"671972","DOI":"10.3389\/fonc.2021.671972","volume":"11","author":"Z Ram","year":"2021","unstructured":"Ram Z et al (2021) Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol 11:671972","journal-title":"Front Oncol"},{"key":"2046_CR409","doi-asserted-by":"crossref","unstructured":"Chen C et al (2022) Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. J Clin Med, 11(19):5855","DOI":"10.3390\/jcm11195855"},{"key":"2046_CR410","doi-asserted-by":"crossref","unstructured":"Schlieper-Scherf S et al (2024) Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models. J Neurooncol 170(1):139\u2013151","DOI":"10.1007\/s11060-024-04786-0"},{"key":"2046_CR411","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fonc.2020.00411","volume":"10","author":"F Bokstein","year":"2020","unstructured":"Bokstein F et al (2020) Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A prospective safety and feasibility study. Front Oncol 10:411","journal-title":"Front Oncol"},{"issue":"2","key":"2046_CR412","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11060-022-04146-w","volume":"160","author":"AS Ali","year":"2022","unstructured":"Ali AS et al (2022) Concurrent chemoradiation and tumor treating fields (TTFields, 200\u00a0kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study. J Neurooncol 160(2):345\u2013350","journal-title":"J Neurooncol"},{"issue":"3","key":"2046_CR413","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11060-020-03466-z","volume":"147","author":"A Song","year":"2020","unstructured":"Song A et al (2020) Initial experience with scalp sparing radiation with concurrent Temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. J Neurooncol 147(3):653\u2013661","journal-title":"J Neurooncol"},{"issue":"8","key":"2046_CR414","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41416-024-02608-8","volume":"130","author":"Q Cao","year":"2024","unstructured":"Cao Q et al (2024) Tumor treating fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. Br J Cancer 130(8):1365\u20131376","journal-title":"Br J Cancer"},{"key":"2046_CR415","doi-asserted-by":"crossref","unstructured":"Yang X, Hu C, Li L (2024) Technical note: computational study on thermal management schemes for tumor-treating fields therapy. Med Phys 51(10):7632\u20137644","DOI":"10.1002\/mp.17296"},{"issue":"1","key":"2046_CR416","doi-asserted-by":"publisher","first-page":"e1838","DOI":"10.1002\/wnan.1838","volume":"15","author":"D Liu","year":"2023","unstructured":"Liu D et al (2023) Nanotechnology Meets glioblastoma multiforme: emerging therapeutic strategies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 15(1):e1838","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"Pt 2","key":"2046_CR417","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.semcancer.2022.06.007","volume":"86","author":"I Khan","year":"2022","unstructured":"Khan I et al (2022) Nanomedicine for glioblastoma: progress and future prospects. Semin Cancer Biol 86(Pt 2):172\u2013186","journal-title":"Semin Cancer Biol"},{"key":"2046_CR418","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jconrel.2020.10.043","volume":"329","author":"Q Fan","year":"2021","unstructured":"Fan Q et al (2021) Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and Superb treatment of orthotopic glioblastoma. J Control Release 329:1139\u20131149","journal-title":"J Control Release"},{"issue":"13","key":"2046_CR419","doi-asserted-by":"publisher","first-page":"e2103689","DOI":"10.1002\/advs.202103689","volume":"9","author":"J Wei","year":"2022","unstructured":"Wei J et al (2022) Immunotherapy of malignant glioma by noninvasive administration of TLR9 agonist CpG Nano-Immunoadjuvant. Adv Sci (Weinh) 9(13):e2103689","journal-title":"Adv Sci (Weinh)"},{"key":"2046_CR420","doi-asserted-by":"publisher","first-page":"102746","DOI":"10.1016\/j.cis.2022.102746","volume":"307","author":"GC Carvalho","year":"2022","unstructured":"Carvalho GC et al (2022) Cetyltrimethylammonium bromide in the synthesis of mesoporous silica nanoparticles: general aspects and in vitro toxicity. Adv Colloid Interface Sci 307:102746","journal-title":"Adv Colloid Interface Sci"},{"issue":"20","key":"2046_CR421","doi-asserted-by":"publisher","first-page":"12716","DOI":"10.1021\/acsnano.3c08993","volume":"18","author":"ZA Chen","year":"2024","unstructured":"Chen ZA et al (2024) Receptor Ligand-Free mesoporous silica nanoparticles: A streamlined strategy for targeted drug delivery across the Blood-Brain barrier. ACS Nano 18(20):12716\u201312736","journal-title":"ACS Nano"},{"key":"2046_CR422","doi-asserted-by":"crossref","unstructured":"Domb AJ et al (2021) Safety evaluation of nanotechnology products. Pharmaceutics, 13(10):1615","DOI":"10.3390\/pharmaceutics13101615"},{"issue":"15","key":"2046_CR423","doi-asserted-by":"publisher","first-page":"e35562","DOI":"10.1016\/j.heliyon.2024.e35562","volume":"10","author":"E Zeynalzadeh","year":"2024","unstructured":"Zeynalzadeh E et al (2024) Navigating the neurological frontier: macromolecular marvels in overcoming blood-brain barrier challenges for advanced drug delivery. Heliyon 10(15):e35562","journal-title":"Heliyon"},{"issue":"17","key":"2046_CR424","doi-asserted-by":"publisher","first-page":"21722","DOI":"10.1021\/acsami.4c04289","volume":"16","author":"TI Hsu","year":"2024","unstructured":"Hsu TI et al (2024) Overcoming the Blood-Brain tumor barrier with Docetaxel-Loaded mesoporous silica nanoparticles for treatment of Temozolomide-Resistant glioblastoma. ACS Appl Mater Interfaces 16(17):21722\u201321735","journal-title":"ACS Appl Mater Interfaces"},{"key":"2046_CR425","doi-asserted-by":"publisher","first-page":"122479","DOI":"10.1016\/j.biomaterials.2024.122479","volume":"306","author":"H Fei","year":"2024","unstructured":"Fei H et al (2024) Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating Temozolomide for synergistic glioblastoma therapy. Biomaterials 306:122479","journal-title":"Biomaterials"},{"issue":"3","key":"2046_CR426","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/acs.molpharmaceut.0c00911","volume":"18","author":"L Wang","year":"2021","unstructured":"Wang L et al (2021) Intranasal delivery of Temozolomide-Conjugated gold nanoparticles functionalized with Anti-EphA3 for glioblastoma targeting. Mol Pharm 18(3):915\u2013927","journal-title":"Mol Pharm"},{"issue":"4","key":"2046_CR427","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1021\/acs.molpharmaceut.2c00083","volume":"19","author":"Y Yu","year":"2022","unstructured":"Yu Y et al (2022) Efficacy of Temozolomide-Conjugated gold nanoparticle photothermal therapy of Drug-Resistant glioblastoma and its mechanism study. Mol Pharm 19(4):1219\u20131229","journal-title":"Mol Pharm"},{"issue":"1","key":"2046_CR428","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41467-019-14036-x","volume":"11","author":"X Meng","year":"2020","unstructured":"Meng X et al (2020) Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways. Nat Commun 11(1):594","journal-title":"Nat Commun"},{"issue":"13","key":"2046_CR429","doi-asserted-by":"publisher","first-page":"eade5321","DOI":"10.1126\/sciadv.ade5321","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang X et al (2023) Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes. Sci Adv 9(13):eade5321","journal-title":"Sci Adv"},{"issue":"21","key":"2046_CR430","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1021\/acs.nanolett.1c02803","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y et al (2021) Circumventing drug resistance pathways with a Nanoparticle-Based photodynamic method. Nano Lett 21(21):9115\u20139123","journal-title":"Nano Lett"},{"issue":"29","key":"2046_CR431","doi-asserted-by":"publisher","first-page":"e2400502","DOI":"10.1002\/adma.202400502","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) Dual-Targeted novel Temozolomide nanocapsules encapsulating siPKM2 inhibit aerobic Glycolysis to sensitize glioblastoma to chemotherapy. Adv Mater 36(29):e2400502","journal-title":"Adv Mater"},{"key":"2046_CR432","doi-asserted-by":"crossref","unstructured":"Wang K et al (2021) SiRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model. Adv Funct Mater, 31(6):2007166","DOI":"10.1002\/adfm.202007166"},{"key":"2046_CR433","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/IJN.S286221","volume":"16","author":"Q Yang","year":"2021","unstructured":"Yang Q et al (2021) Gene therapy for Drug-Resistant glioblastoma via Lipid-Polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomed 16:185\u2013199","journal-title":"Int J Nanomed"},{"key":"2046_CR434","doi-asserted-by":"crossref","unstructured":"Morimoto T et al (2021) CRISPR-Cas9-Mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells. Int J Mol Sci, 22(7):3489","DOI":"10.3390\/ijms22073489"},{"issue":"3","key":"2046_CR435","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","volume":"25","author":"K Nemeth","year":"2024","unstructured":"Nemeth K et al (2024) Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet 25(3):211\u2013232","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2046_CR436","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1038\/s41467-024-53613-7","volume":"15","author":"M Luciani","year":"2024","unstructured":"Luciani M et al (2024) Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice. Nat Commun 15(1):9433","journal-title":"Nat Commun"},{"issue":"1","key":"2046_CR437","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s12885-023-11418-9","volume":"23","author":"CA Vincent","year":"2023","unstructured":"Vincent CA et al (2023) Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to Temozolomide. BMC Cancer 23(1):945","journal-title":"BMC Cancer"},{"issue":"1","key":"2046_CR438","doi-asserted-by":"publisher","first-page":"17639","DOI":"10.1038\/s41598-024-68626-x","volume":"14","author":"ICN Avenel","year":"2024","unstructured":"Avenel ICN et al (2024) GDNF\/GFRA1 signaling contributes to chemo- and radioresistance in glioblastoma. Sci Rep 14(1):17639","journal-title":"Sci Rep"},{"issue":"11","key":"2046_CR439","doi-asserted-by":"publisher","first-page":"113339","DOI":"10.1016\/j.celrep.2023.113339","volume":"42","author":"IL Tan","year":"2023","unstructured":"Tan IL et al (2023) Targeting the non-coding genome and Temozolomide signature enables CRISPR-mediated glioma Oncolysis. Cell Rep 42(11):113339","journal-title":"Cell Rep"},{"issue":"12","key":"2046_CR440","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41565-024-01769-0","volume":"19","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Polymer-locking fusogenic liposomes for glioblastoma-targeted SiRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 19(12):1869\u20131879","journal-title":"Nat Nanotechnol"},{"issue":"16","key":"2046_CR441","doi-asserted-by":"publisher","first-page":"eabm8011","DOI":"10.1126\/sciadv.abm8011","volume":"8","author":"Y Zou","year":"2022","unstructured":"Zou Y et al (2022) Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv 8(16):eabm8011","journal-title":"Sci Adv"},{"key":"2046_CR442","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jconrel.2022.09.046","volume":"351","author":"W Ruan","year":"2022","unstructured":"Ruan W et al (2022) Brain-targeted CRISPR\/Cas9 nanomedicine for effective glioblastoma therapy. J Control Release 351:739\u2013751","journal-title":"J Control Release"},{"key":"2046_CR443","doi-asserted-by":"crossref","unstructured":"Wong SC, Kamarudin MNA, Naidu R (2023) Anticancer mechanism of flavonoids on High-Grade Adult-Type diffuse gliomas. Nutrients, 15(4):797","DOI":"10.3390\/nu15040797"},{"key":"2046_CR444","doi-asserted-by":"crossref","unstructured":"Zhai K et al (2021) Flavonoids synergistically enhance the Anti-Glioblastoma effects of chemotherapeutic drugs. Biomolecules, 11(12):1841","DOI":"10.3390\/biom11121841"},{"key":"2046_CR445","doi-asserted-by":"publisher","first-page":"120609","DOI":"10.1016\/j.lfs.2022.120609","volume":"301","author":"S Daisy Precilla","year":"2022","unstructured":"Daisy Precilla S et al (2022) Integration of synthetic and natural derivatives revives the therapeutic potential of Temozolomide against glioma- an in vitro and in vivo perspective. Life Sci 301:120609","journal-title":"Life Sci"},{"issue":"2","key":"2046_CR446","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1007\/s12035-021-02674-6","volume":"59","author":"Q Dong","year":"2022","unstructured":"Dong Q et al (2022) Biochanin A sensitizes glioblastoma to Temozolomide by inhibiting autophagy. Mol Neurobiol 59(2):1262\u20131272","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2046_CR447","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/13880209.2022.2157841","volume":"61","author":"L Wang","year":"2023","unstructured":"Wang L et al (2023) Therapeutic effects of Bombax ceiba flower aqueous extracts against loperamide-induced constipation in mice. Pharm Biol 61(1):125\u2013134","journal-title":"Pharm Biol"},{"key":"2046_CR448","doi-asserted-by":"crossref","unstructured":"Zhai K et al (2020) Curcumin\u2019s Beneficial Effects on Neuroblastoma: Mechanisms, Challenges, and Potential Solutions. Biomolecules, 10(11):1469","DOI":"10.3390\/biom10111469"},{"issue":"4","key":"2046_CR449","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1021\/acsptsci.2c00012","volume":"6","author":"AB Kunnumakkara","year":"2023","unstructured":"Kunnumakkara AB et al (2023) Role of turmeric and Curcumin in prevention and treatment of chronic diseases: lessons learned from clinical trials. ACS Pharmacol Transl Sci 6(4):447\u2013518","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2046_CR450","doi-asserted-by":"crossref","unstructured":"Zhai K et al (2021) Natural compounds in glioblastoma therapy: preclinical insights, mechanistic pathways, and outlook. Cancers (Basel), 13(10):2317","DOI":"10.3390\/cancers13102317"},{"key":"2046_CR451","doi-asserted-by":"crossref","unstructured":"Wong SC, Kamarudin MNA, Naidu R (2021) Anticancer mechanism of Curcumin on human glioblastoma. Nutrients, 13(3):950","DOI":"10.3390\/nu13030950"},{"key":"2046_CR452","doi-asserted-by":"publisher","first-page":"1036809","DOI":"10.3389\/fcell.2022.1036809","volume":"10","author":"O Beylerli","year":"2022","unstructured":"Beylerli O et al (2022) Therapeutic effect of natural polyphenols against glioblastoma. Front Cell Dev Biol 10:1036809","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2046_CR453","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1007\/s11064-022-03666-1","volume":"47","author":"M Mohamadian","year":"2022","unstructured":"Mohamadian M et al (2022) Review on the therapeutic potential of Curcumin and its derivatives on glioma biology. Neurochem Res 47(10):2936\u20132953","journal-title":"Neurochem Res"},{"issue":"11","key":"2046_CR454","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41419-021-04259-6","volume":"12","author":"G Iegiani","year":"2021","unstructured":"Iegiani G, Di Cunto F, Pallavicini G (2021) Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors. Cell Death Dis 12(11):956","journal-title":"Cell Death Dis"},{"issue":"4","key":"2046_CR455","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/CM9.0000000000002976","volume":"137","author":"L Yi","year":"2024","unstructured":"Yi L et al (2024) Chronic stress as an emerging risk factor for the development and progression of glioma. Chin Med J (Engl) 137(4):394\u2013407","journal-title":"Chin Med J (Engl)"},{"issue":"13","key":"2046_CR456","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.2174\/1871520622666211221144739","volume":"22","author":"S Datta","year":"2022","unstructured":"Datta S, Luthra R, Bharadvaja N (2022) Medicinal plants for glioblastoma treatment. Anticancer Agents Med Chem 22(13):2367\u20132384","journal-title":"Anticancer Agents Med Chem"},{"key":"2046_CR457","doi-asserted-by":"crossref","unstructured":"Mazumder K et al (2022) A review on mechanistic insight of plant derived anticancer bioactive phytocompounds and their structure activity relationship. Molecules, 27(9):3036","DOI":"10.3390\/molecules27093036"},{"key":"2046_CR458","doi-asserted-by":"crossref","unstructured":"Lipi\u0144ska MM et al (2023) Active compounds with medicinal potential found in maxillariinae Benth. (Orchidaceae Juss.) Representatives-A review. Int J Mol Sci, 24(1):739","DOI":"10.3390\/ijms24010739"},{"key":"2046_CR459","doi-asserted-by":"crossref","unstructured":"Koklesova L et al (2020) Carotenoids in Cancer Metastasis-Status quo and outlook. Biomolecules, 10(12):1653","DOI":"10.3390\/biom10121653"},{"key":"2046_CR460","doi-asserted-by":"publisher","first-page":"1231006","DOI":"10.3389\/fphar.2023.1231006","volume":"14","author":"G Anywar","year":"2023","unstructured":"Anywar G, Muhumuza E (2023) Bioactivity and toxicity of coumarins from African medicinal plants. Front Pharmacol 14:1231006","journal-title":"Front Pharmacol"},{"key":"2046_CR461","doi-asserted-by":"crossref","unstructured":"Jang WY, Kim MY, Cho JY (2022) Antioxidant, Anti-Inflammatory, Anti-Menopausal, and Anti-Cancer Effects of Lignans and Their Metabolites. Int J Mol Sci, 23(24):15482","DOI":"10.3390\/ijms232415482"},{"key":"2046_CR462","doi-asserted-by":"crossref","unstructured":"Sokolov MN et al (2024) The effects of the steroids 5-Androstenediol and dehydroepiandrosterone and their synthetic derivatives on the viability of K562, HeLa, and Wi-38 cells and the Luminol-Stimulated chemiluminescence of peripheral blood mononuclear cells from healthy volunteers. Biomolecules, 14(3):373","DOI":"10.3390\/biom14030373"},{"key":"2046_CR463","doi-asserted-by":"publisher","first-page":"105959","DOI":"10.1016\/j.phrs.2021.105959","volume":"175","author":"S Pucci","year":"2022","unstructured":"Pucci S et al (2022) Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based \u03b17- and \u03b19-nicotinic ligands on glioblastoma cells. Pharmacol Res 175:105959","journal-title":"Pharmacol Res"},{"key":"2046_CR464","doi-asserted-by":"crossref","unstructured":"Chauhan SS et al (2020) Pectin-Tannic acid Nano-Complexes promote the delivery and bioactivity of drugs in pancreatic Cancer cells. Pharmaceutics, 12(3):285","DOI":"10.3390\/pharmaceutics12030285"},{"key":"2046_CR465","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2020.00025","volume":"11","author":"Y Zhu","year":"2020","unstructured":"Zhu Y et al (2020) Celastrol suppresses glioma vasculogenic mimicry formation and angiogenesis by blocking the PI3K\/Akt\/mTOR signaling pathway. Front Pharmacol 11:25","journal-title":"Front Pharmacol"},{"key":"2046_CR466","doi-asserted-by":"crossref","unstructured":"Kim Y et al (2022) Drug-Disease association prediction using heterogeneous networks for computational drug repositioning. Biomolecules, 12(10):1497","DOI":"10.3390\/biom12101497"},{"issue":"1","key":"2046_CR467","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"2046_CR468","doi-asserted-by":"publisher","first-page":"1243286","DOI":"10.3389\/fphar.2023.1243286","volume":"14","author":"C Xu","year":"2023","unstructured":"Xu C et al (2023) Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential. Front Pharmacol 14:1243286","journal-title":"Front Pharmacol"},{"issue":"9","key":"2046_CR469","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X et al (2021) Ferroptosis: machinery and regulation. Autophagy 17(9):2054\u20132081","journal-title":"Autophagy"},{"issue":"4","key":"2046_CR470","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2046_CR471","doi-asserted-by":"publisher","first-page":"2004680","DOI":"10.1002\/advs.202004680","volume":"8","author":"J Guo","year":"2021","unstructured":"Guo J et al (2021) A combined model of human iPSC-Derived liver organoids and hepatocytes reveals ferroptosis in DGUOK mutant MtDNA depletion syndrome. Adv Sci (Weinh) 8(10):2004680","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"2046_CR472","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jpha.2021.06.002","volume":"11","author":"E Nottingham","year":"2021","unstructured":"Nottingham E et al (2021) Synergistic effects of Methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. J Pharm Anal 11(6):799\u2013807","journal-title":"J Pharm Anal"},{"issue":"5","key":"2046_CR473","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","volume":"15","author":"JC Yang","year":"2020","unstructured":"Yang JC et al (2020) Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J Thorac Oncol 15(5):803\u2013815","journal-title":"J Thorac Oncol"},{"issue":"16","key":"2046_CR474","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1200\/JCO.22.02547","volume":"41","author":"LV Sequist","year":"2023","unstructured":"Sequist LV et al (2023) Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 41(16):2869\u20132876","journal-title":"J Clin Oncol"},{"issue":"8","key":"2046_CR475","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B (2023) Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol 19(8):460\u2013476","journal-title":"Nat Rev Endocrinol"},{"key":"2046_CR476","doi-asserted-by":"publisher","first-page":"1096614","DOI":"10.3389\/fphar.2023.1096614","volume":"14","author":"SS Kuduvalli","year":"2023","unstructured":"Kuduvalli SS et al (2023) A combination of Metformin and Epigallocatechin gallate potentiates glioma chemotherapy in vivo. Front Pharmacol 14:1096614","journal-title":"Front Pharmacol"},{"issue":"1","key":"2046_CR477","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40880-019-0424-2","volume":"39","author":"JH Tang","year":"2019","unstructured":"Tang JH et al (2019) Bortezomib inhibits growth and sensitizes glioma to Temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Cancer Commun (Lond) 39(1):81","journal-title":"Cancer Commun (Lond)"},{"key":"2046_CR478","doi-asserted-by":"publisher","first-page":"933655","DOI":"10.3389\/fphar.2022.933655","volume":"13","author":"S Zhong","year":"2022","unstructured":"Zhong S et al (2022) Disulfiram in glioma: literature review of drug repurposing. Front Pharmacol 13:933655","journal-title":"Front Pharmacol"},{"issue":"1","key":"2046_CR479","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","volume":"40","author":"S Matteoni","year":"2021","unstructured":"Matteoni S et al (2021) Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via Endoplasmic reticulum stress and unfolded protein response. J Exp Clin Cancer Res 40(1):347","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2046_CR480","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s12967-024-05501-3","volume":"22","author":"P Matarrese","year":"2024","unstructured":"Matarrese P et al (2024) Chlorpromazine overcomes Temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways. J Transl Med 22(1):667","journal-title":"J Transl Med"},{"key":"2046_CR481","doi-asserted-by":"publisher","first-page":"114326","DOI":"10.1016\/j.ejpb.2024.114326","volume":"200","author":"MJ Ramalho","year":"2024","unstructured":"Ramalho MJ et al (2024) Chitosan-PLGA mucoadhesive nanoparticles for gemcitabine repurposing for glioblastoma therapy. Eur J Pharm Biopharm 200:114326","journal-title":"Eur J Pharm Biopharm"},{"issue":"14","key":"2046_CR482","doi-asserted-by":"publisher","first-page":"7927","DOI":"10.1039\/D0NR01647K","volume":"12","author":"PY Liyanage","year":"2020","unstructured":"Liyanage PY et al (2020) Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood-brain barrier via carbon nitride Dots. Nanoscale 12(14):7927\u20137938","journal-title":"Nanoscale"},{"key":"2046_CR483","doi-asserted-by":"publisher","first-page":"627229","DOI":"10.3389\/fonc.2021.627229","volume":"11","author":"M Cruz-Burgos","year":"2021","unstructured":"Cruz-Burgos M et al (2021) New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil. Front Oncol 11:627229","journal-title":"Front Oncol"},{"key":"2046_CR484","doi-asserted-by":"crossref","unstructured":"Nayak R, Mallick B (2024) BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant glioblastoma using target gene expression and virtual drug screening. Cancer Genet, 288\u2013289:20\u201331","DOI":"10.1016\/j.cancergen.2024.08.082"},{"key":"2046_CR485","doi-asserted-by":"crossref","unstructured":"Kadasah SF et al (2024) Beyond psychotropic: potential repurposing of Fluoxetine toward Cancer therapy. Int J Mol Sci, 25(12):6314","DOI":"10.3390\/ijms25126314"},{"key":"2046_CR486","doi-asserted-by":"crossref","unstructured":"Mubeen S et al (2024) Iloperidone and Temozolomide synergistically inhibit growth, migration and enhance apoptosis in glioblastoma cells. Biomedicines, 12(6):1134","DOI":"10.3390\/biomedicines12061134"},{"key":"2046_CR487","doi-asserted-by":"publisher","first-page":"116844","DOI":"10.1016\/j.taap.2024.116844","volume":"484","author":"I Bramatti","year":"2024","unstructured":"Bramatti I et al (2024) Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors. Toxicol Appl Pharmacol 484:116844","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2046_CR488","first-page":"vdae014","volume":"6","author":"RK Driscoll","year":"2024","unstructured":"Driscoll RK et al (2024) A multi-institutional phase I study of Acetazolamide with Temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma. Neurooncol Adv 6(1):vdae014","journal-title":"Neurooncol Adv"},{"key":"2046_CR489","doi-asserted-by":"publisher","first-page":"114555","DOI":"10.1016\/j.biopha.2023.114555","volume":"162","author":"F You","year":"2023","unstructured":"You F et al (2023) Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances Temozolomide cytotoxicity. Biomed Pharmacother 162:114555","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2046_CR490","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1007\/s11095-022-03399-4","volume":"39","author":"A Yadav","year":"2022","unstructured":"Yadav A et al (2022) Repurposing an antiepileptic drug for the treatment of glioblastoma. Pharm Res 39(11):2871\u20132883","journal-title":"Pharm Res"},{"issue":"1","key":"2046_CR491","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13014-024-02408-7","volume":"19","author":"NB Pepper","year":"2024","unstructured":"Pepper NB et al (2024) ALA-RDT in GBM: protocol of the phase I\/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma. Radiat Oncol 19(1):11","journal-title":"Radiat Oncol"},{"issue":"1","key":"2046_CR492","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13046-021-02135-x","volume":"40","author":"R Vengoji","year":"2021","unstructured":"Vengoji R et al (2021) Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for glioblastoma. J Exp Clin Cancer Res 40(1):335","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"2046_CR493","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41401-021-00724-2","volume":"42","author":"ZZ Liu","year":"2021","unstructured":"Liu ZZ et al (2021) Identification of Pimavanserin tartrate as a potent Ca(2+)-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Acta Pharmacol Sin 42(11):1860\u20131874","journal-title":"Acta Pharmacol Sin"},{"key":"2046_CR494","doi-asserted-by":"crossref","unstructured":"Hijazi MA, Gessner A, El-Najjar N (2023) Repurposing of chronically used drugs in Cancer therapy: A chance to Grasp. Cancers (Basel), 15(12):3199","DOI":"10.3390\/cancers15123199"},{"issue":"5","key":"2046_CR495","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.18632\/aging.202539","volume":"13","author":"J Shi","year":"2021","unstructured":"Shi J et al (2021) Nicardipine sensitizes Temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. Aging 13(5):6820\u20136831","journal-title":"Aging"},{"key":"2046_CR496","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12935-020-1144-z","volume":"20","author":"J Wu","year":"2020","unstructured":"Wu J et al (2020) Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int 20:71","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2046_CR497","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1038\/s41598-019-41380-1","volume":"9","author":"V Pandey","year":"2019","unstructured":"Pandey V et al (2019) Roscovitine effectively enhances antitumor activity of Temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis. Sci Rep 9(1):5012","journal-title":"Sci Rep"},{"issue":"1","key":"2046_CR498","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41598-019-39427-4","volume":"9","author":"W Ha","year":"2019","unstructured":"Ha W et al (2019) Ibudilast sensitizes glioblastoma to Temozolomide by targeting macrophage migration inhibitory factor (MIF). Sci Rep 9(1):2905","journal-title":"Sci Rep"},{"issue":"10","key":"2046_CR499","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/neuonc\/noac036","volume":"24","author":"E van Kessel","year":"2022","unstructured":"van Kessel E et al (2022) Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma. Neuro Oncol 24(10):1660\u20131670","journal-title":"Neuro Oncol"},{"issue":"7","key":"2046_CR500","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/ijc.31912","volume":"144","author":"TC Johannessen","year":"2019","unstructured":"Johannessen TC et al (2019) Thioridazine inhibits autophagy and sensitizes glioblastoma cells to Temozolomide. Int J Cancer 144(7):1735\u20131745","journal-title":"Int J Cancer"},{"issue":"8","key":"2046_CR501","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41388-020-01622-3","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene 40(8):1425\u20131439","journal-title":"Oncogene"},{"key":"2046_CR502","doi-asserted-by":"crossref","unstructured":"Chinyama HA et al (2023) Identification of CDK1, PBK, and CHEK1 as an oncogenic signature in glioblastoma: A bioinformatics approach to repurpose Dapagliflozin as a therapeutic agent. Int J Mol Sci, 24(22):16396","DOI":"10.3390\/ijms242216396"},{"key":"2046_CR503","doi-asserted-by":"publisher","first-page":"115507","DOI":"10.1016\/j.ejmech.2023.115507","volume":"257","author":"HS Summers","year":"2023","unstructured":"Summers HS et al (2023) Discovery of new imidazotetrazinones with potential to overcome tumor resistance. Eur J Med Chem 257:115507","journal-title":"Eur J Med Chem"},{"issue":"17","key":"2046_CR504","doi-asserted-by":"publisher","first-page":"7852","DOI":"10.1021\/jacs.2c01932","volume":"144","author":"M Gazvoda","year":"2022","unstructured":"Gazvoda M et al (2022) Palladium-Mediated incorporation of Carboranes into small molecules, peptides, and proteins. J Am Chem Soc 144(17):7852\u20137860","journal-title":"J Am Chem Soc"},{"issue":"5","key":"2046_CR505","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/med.21964","volume":"43","author":"P Coghi","year":"2023","unstructured":"Coghi P et al (2023) Next generation of Boron neutron capture therapy (BNCT) agents for cancer treatment. Med Res Rev 43(5):1809\u20131830","journal-title":"Med Res Rev"},{"key":"2046_CR506","doi-asserted-by":"crossref","unstructured":"Xiang J et al (2022) A boronated derivative of Temozolomide showing enhanced efficacy in Boron neutron capture therapy of glioblastoma. Cells, 11(7):1173","DOI":"10.3390\/cells11071173"},{"issue":"10","key":"2046_CR507","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1016\/j.xphs.2021.06.025","volume":"110","author":"Y Yu","year":"2021","unstructured":"Yu Y et al (2021) Synthesis and characterization of a series of Temozolomide esters and its Anti-glioma study. J Pharm Sci 110(10):3431\u20133438","journal-title":"J Pharm Sci"},{"issue":"2","key":"2046_CR508","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41419-022-04590-6","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X et al (2022) Acquired Temozolomide resistance in MGMT(low) gliomas is associated with regulation of homologous recombination repair by ROCK2. Cell Death Dis 13(2):138","journal-title":"Cell Death Dis"},{"issue":"1","key":"2046_CR509","first-page":"vdae095","volume":"6","author":"RO Minea","year":"2024","unstructured":"Minea RO et al (2024) NEO212, Temozolomide conjugated to NEO100, exerts superior therapeutic activity over Temozolomide in preclinical chemoradiation models of glioblastoma. Neurooncol Adv 6(1):vdae095","journal-title":"Neurooncol Adv"},{"key":"2046_CR510","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2018.10.034","volume":"442","author":"NI Mar\u00edn-Ramos","year":"2019","unstructured":"Mar\u00edn-Ramos NI et al (2019) NEO212, a conjugate of Temozolomide and Perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma. Cancer Lett 442:170\u2013180","journal-title":"Cancer Lett"},{"key":"2046_CR511","doi-asserted-by":"publisher","first-page":"1441460","DOI":"10.3389\/fonc.2024.1441460","volume":"14","author":"WH Bae","year":"2024","unstructured":"Bae WH, Maraka S, Daher A (2024) Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration. Front Oncol 14:1441460","journal-title":"Front Oncol"},{"issue":"3","key":"2046_CR512","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","volume":"11","author":"JG Nicholson","year":"2021","unstructured":"Nicholson JG, Fine HA (2021) Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 11(3):575\u2013590","journal-title":"Cancer Discov"},{"key":"2046_CR513","doi-asserted-by":"publisher","first-page":"676301","DOI":"10.3389\/fimmu.2021.676301","volume":"12","author":"MW Yu","year":"2021","unstructured":"Yu MW, Quail DF (2021) Immunotherapy for glioblastoma: current progress and challenges. Front Immunol 12:676301","journal-title":"Front Immunol"},{"key":"2046_CR514","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2018.05.008","volume":"281","author":"LP Ganipineni","year":"2018","unstructured":"Ganipineni LP, Danhier F, Pr\u00e9at V (2018) Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release 281:42\u201357","journal-title":"J Control Release"},{"key":"2046_CR515","doi-asserted-by":"crossref","unstructured":"Yun CW et al (2020) The dual role of autophagy in Cancer development and a therapeutic strategy for Cancer by targeting autophagy. Int J Mol Sci 22(1):179","DOI":"10.3390\/ijms22010179"},{"issue":"24","key":"2046_CR516","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1007\/s00018-020-03569-w","volume":"77","author":"CE Badr","year":"2020","unstructured":"Badr CE et al (2020) Metabolic heterogeneity and adaptability in brain tumors. Cell Mol Life Sci 77(24):5101\u20135119","journal-title":"Cell Mol Life Sci"},{"key":"2046_CR517","doi-asserted-by":"publisher","first-page":"114118","DOI":"10.1016\/j.addr.2022.114118","volume":"182","author":"U Dirnagl","year":"2022","unstructured":"Dirnagl U et al (2022) Reproducibility, relevance and reliability as barriers to efficient and credible biomedical technology translation. Adv Drug Deliv Rev 182:114118","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2046_CR518","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40169-018-0211-8","volume":"7","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Nandi S, Bhattacharjee S (2018) Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med 7(1):33","journal-title":"Clin Transl Med"},{"key":"2046_CR519","doi-asserted-by":"publisher","first-page":"e15571","DOI":"10.7717\/peerj.15571","volume":"11","author":"Y Wu","year":"2023","unstructured":"Wu Y et al (2023) Functionalized nanoparticles crossing the brain-blood barrier to target glioma cells. PeerJ 11:e15571","journal-title":"PeerJ"},{"key":"2046_CR520","doi-asserted-by":"crossref","unstructured":"Meng W et al (2022) Overcoming radiation resistance in gliomas by targeting metabolism and DNA repair pathways. Int J Mol Sci 23(4):2246","DOI":"10.3390\/ijms23042246"},{"key":"2046_CR521","doi-asserted-by":"publisher","first-page":"1299064","DOI":"10.3389\/fimmu.2023.1299064","volume":"14","author":"TA Mishchenko","year":"2023","unstructured":"Mishchenko TA et al (2023) Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy. Front Immunol 14:1299064","journal-title":"Front Immunol"},{"key":"2046_CR522","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.semcancer.2023.03.006","volume":"91","author":"J Luo","year":"2023","unstructured":"Luo J et al (2023) Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma. Semin Cancer Biol 91:110\u2013123","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2046_CR523","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA et al (2022) Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 40(4):403\u2013426","journal-title":"J Clin Oncol"},{"issue":"11","key":"2046_CR524","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","volume":"23","author":"T Walbert","year":"2021","unstructured":"Walbert T et al (2021) SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 23(11):1835\u20131844","journal-title":"Neuro Oncol"},{"issue":"6","key":"2046_CR525","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/neuonc\/noab240","volume":"24","author":"AK Park","year":"2022","unstructured":"Park AK et al (2022) Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. Neuro Oncol 24(6):964\u2013973","journal-title":"Neuro Oncol"},{"issue":"5","key":"2046_CR526","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze AV et al (2015) A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92(5):986\u2013992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2046_CR527","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M et al (2011) Prolonged survival with valproic acid use in the EORTC\/NCIC Temozolomide trial for glioblastoma. Neurology 77(12):1156\u20131164","journal-title":"Neurology"},{"key":"2046_CR528","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13014-015-0527-0","volume":"10","author":"LB Shields","year":"2015","unstructured":"Shields LB et al (2015) Dexamethasone administration during definitive radiation and Temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 10:222","journal-title":"Radiat Oncol"},{"key":"2046_CR529","doi-asserted-by":"crossref","unstructured":"Gonzalez-Aponte MF et al (2025) Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host. Cancer Cell 43(1):144\u2013160","DOI":"10.1016\/j.ccell.2024.11.012"},{"issue":"3","key":"2046_CR530","doi-asserted-by":"publisher","first-page":"158","DOI":"10.14791\/btrt.2022.0018","volume":"10","author":"H Ha","year":"2022","unstructured":"Ha H, Lim JH (2022) Managing side effects of cytotoxic chemotherapy in patients with high grade gliomas. Brain Tumor Res Treat 10(3):158\u2013163","journal-title":"Brain Tumor Res Treat"},{"issue":"23","key":"2046_CR531","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R et al (2017) Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 318(23):2306\u20132316","journal-title":"JAMA"},{"issue":"6","key":"2046_CR532","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M et al (2017) European association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315\u2013e329","journal-title":"Lancet Oncol"},{"key":"2046_CR533","doi-asserted-by":"crossref","unstructured":"van den Bent MJ et al (2017) Interim results from the CATNON trial (EORTC study 26053\u2013\u200922054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103):1645\u20131653","DOI":"10.1016\/S0140-6736(17)31442-3"},{"key":"2046_CR534","doi-asserted-by":"crossref","unstructured":"Fanizzi C et al (2025) Optimal MGMT promoter methylation cut-off to predict better survival in glioblastoma patients undergoing gross-total resection. J Neurosurg Sci","DOI":"10.23736\/S0390-5616.25.06421-5"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02046-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02046-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T23:44:57Z","timestamp":1749080697000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02046-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":534,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02046-4","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}